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CHAPTER 1: INTRODUCTION
1.1 Hereditary cancer predisposition
Cancer is a complex disease defined by uncontrolled cell growth that eventually leads to
cells invading other nearby organs. It remains one of the leading causes of morbidity and
mortality worldwide and places an enormous financial burden on those affected. Startlingly, the
estimated financial annual cost of cancer is projected to reach $158 billion by 2020 in the US
alone (Mariotto et al., 2011). There are over 100 types of cancer, classified by the organ of
origin. What causes this uncontrolled growth is not always clear. The advent of molecular
profiling has helped to uncover mechanisms underlying tumor development and at the same time
has helped to further classify tumors by sub-type. Decades of research have shown various
environmental carcinogens to play a role as well as genetic and epigenetic contributions.
Tumorigenesis is a multistep genetic process and usually begins with a somatic mutation
in a tumor suppressor gene (involved in DNA repair, apoptosis, etc.) or oncogene. For tumor
suppressor genes, an additional somatic mutation causing a loss of heterozygosity (LOH) of the
wild type (WT) allele is often necessary for tumor progression. This observation confirmed
Knudson’s two-hit hypothesis (Knudson, 1971). Individuals who carry a germline variant in a
tumor suppressor gene are at significantly higher risk than the general population as they are
born already with the “first hit”. These individuals are said to have an inherited cancer risk
predisposition (Figure 1).
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Figure 1. Non-hereditary and hereditary initiation of tumorigenesis by two-hit hypotheses
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1.2 Ovarian cancer
Ovarian cancer (OVCA) begins in the ovaries or Fallopian tubes, which are part of the
female reproductive system (Figure 2). Ovaries are almond in size and shape and are responsible
for ova and female hormone production. Ovarian cancer is less common than other cancers, such
as breast or colon cancer, and accounts for approximately 3% of all of cancers in women
(National Cancer Institute, 2013). Still, it is estimated that over 21,000 new cases of ovarian
cancer occur yearly, in the United States alone (American Cancer Society, 2014). Yet, despite
being ranked as the 11th most common cancer in women, it is the 5th leading cause of cancerrelated death among women, and is the top cause of female reproductive cancer deaths (Bell et
al., 2011). The five year survival rate at diagnosis averages just 44.2% (American Cancer
Society, 2014). The high mortality rate is mostly due to poor early detection as only 15% of
patients are diagnosed in early, more treatable stages (National Cancer Institute, 2013). Accurate
risk prediction holds promise as prophylactic measures can be taken before the cancer develops
(Bast, Hennessy, and Mills, 2009).
Recent studies suggest that at least 25% of epithelial ovarian cancer cases arise due to an
inherited risk factor (Walsh et al., 2011).

Hereditary breast and ovarian cancer (HBOC)

syndromes are, for the most part, autosomal dominant genetic disorders in which germline
mutations elevate lifetime risk of developing breast or ovarian cancer up to as much as 87% and
49% respectively (Antoniou et al. , 2003; Risch et al. , 2001; Claus et al. , 1996). The risk
among the general population is 12% for breast and 1.4% for ovarian cancer (Plevová et al.
2009). Therefore, women with a personal or family history of OVCA and/or young onset and/or
multiple cases of breast cancer are counseled to consider genetic screening per guidelines of the
National Comprehensive Cancer Network (NCCN) (Genetic/Familial High-Risk Assessment:
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Breast and Ovarian www.nccn.org). Current testing panels mostly feature genes involved in
DNA repair and cell cycle control, such as BRCA1 and BRCA2, which explain the majority of
inherited ovarian and breast cancer, as well as 22 other genes including ATM, BARD1, BRCA1,
BRCA2, BRIP1, CDH1, CHK2, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2,
RAD50, RAD51C, RAD51D, SMARCA4, and TP53. Additional genes tested that are not directly
involved with DNA repair or cell cycle control include; EPCAM, NF1, PTEN and STK11.
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Figure 2. Diagram of the female reproductive system
Source: https://www.womenshealth.gov/cancer/ovarian-cancer. This image is free of copyright
restrictions and may be copied, reproduced, or duplicated without permission of the Office on
Women’s Health in the U.S. Department of Health and Human Services
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1.2.1 Diagnostics and detection
While significant advances in diagnosis and treatment for various other forms of cancer
have led to excitement in the field of oncology, OVCA mortality rates have only slightly
decreased since "the war on cancer" was officially declared in 1971 (NIH Surveillance,
Epidemiology and End Results Program: Cancer of the Ovary - Cancer Stat Facts, 2017). This is
mostly due to a lack of advancement in early detection since survival rates depend greatly on the
stage at which the cancer is diagnosed. Women diagnosed before the cancer has had a chance to
metastasize have a dramatically increased five-year survival rate relative to those diagnosed at a
more advanced stage. The 5-year survival rate is over 90% with diagnosis at stage I and standard
treatment. Unfortunately, less than 20% percent of OVCA patients are diagnosed in the early
stages of the disease (National Cancer Institute, 2013). Ovarian cancer is difficult to detect early
since a woman may be asymptomatic until the cancer has advanced to Stages 3 and 4. Unlike
breast cancer, tumors that grow in the ovaries or Fallopian tubes are not readily detectable by
self-examination.

When symptoms do appear, they are often vague and may not illicit

immediate medical care. Symptoms include: abdominal pain, vaginal bleeding, weight loss,
abnormal periods, back pain, bloating, nausea and vomiting, etc (NIH, 2017).

Therefore,

accurate risk assessment to identify likely cases prior to occurrence holds much promise since
prophylactic surgery can virtually eliminate a woman’s chances of developing OVCA.
1.2.2 Risk factors
Today, in the United States, the average woman’s lifetime risk of developing invasive
ovarian cancer is 1 in 75 (National Cancer Institute 2013; Risk Factors - Ovarian Cancer
Research Fund Alliance, 2017). While women of all ages are susceptible to developing ovarian
cancer, incidences are highest in women 55-64 years of age (National Cancer Institute, 2013;
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Risk Factors - Ovarian Cancer Research Fund Alliance, 2017). There are, in addition to age,
multiple factors that affect a women's lifetime risk. Caucasian ancestry, nulliparity, infertility,
the use of hormonal replacement therapy, and obesity have all been found to correlate with an
increased risk (National Cancer Institute, 2013; Risk Factors - Ovarian Cancer Research Fund
Alliance, 2017). The reproductive history is thought to be important to ovarian cancer risk since
the risk increases with the amount of menstrual cycles a woman has during her fertile years.
Therefore, a woman is at an increased risk if she has never had any children, has begun
menstruation before the age of 12, started menopause after 50, or has never used oral
contraceptives or undergone tubal ligation (National Cancer Institute, 2013; Risk Factors Ovarian Cancer Research Fund Alliance, 2017).
However, none of these factors are strong enough to predict the risk of ovarian cancer
occurrence with enough conviction as to prompt prophylactic surgery. The single most
influential factor on a woman's risk is her family history (National Cancer Institute, 2013; Risk
Factors - Ovarian Cancer Research Fund Alliance, 2017; Chun and Ford, 2012; Trifonov,
Todorova, and Uzunova, 2001). While the average woman’s lifetime risk is just 1.4%, those
with a first degree relative diagnosed with OVCA have a 5% lifetime risk (Centers for Disease
Control and Prevention, 2017). Therefore, women with a family history of ovarian cancer are
encouraged to undergo genetic risk assessment.

1.3 Genetic risk assessment
Hereditary breast and ovarian cancer (HBOC) syndromes are for the most part autosomal
dominant genetic disorders where germline mutations elevate lifetime risk of developing breast
or ovarian cancer up to 87% and 49% respectively (Risch et al., 2001; Claus et al., 1996).
Genetic testing can identify those at risk before the cancer develops, which in some cases leads
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to prophylactic measures. For those already with a diagnosis, testing for germline mutations can
inform risk of additional cancers as well as identify risk in unaffected relatives who may also
carry the same mutation. Therefore, identifying those at increased risk due to genetic inheritance
can lead to improved clinical outcomes (Narod et al., 2013). A diagnosis of HBOC is considered
when either ovarian or breast cancer occurs on the same side of a family for multiple generations
or multiple first-degree relatives (Kobayashi et al., 2013). Specifically, the likelihood of familial
risk for HBOC increases with each of the following criteria (Clinical, Guidelines, and Guidelines
2018):


A diagnosis of breast or OVCA under the age of 45



OVCA at any age



A blood relative diagnosed with breast cancer before 50 years of age



Breast/OVCA across multiple generations on the same side of the family



A second diagnosis of breast cancer or ovarian cancer in the same individual



Breast cancer in a male blood relative



Breast or ovarian and pancreatic cancer all on the same side of the family



A history of cancer in a family of Ashkenazi Jewish ancestry

Two genes commonly associated with HBOC are BRCA1 and BRCA2, while other less
common mutations have been found in tumor suppressor genes such as TP53, PTEN, CDH1,
ATM, CHK2 or PALB2, etc. (Kobayashi et al., 2013). Another inherited syndrome, Lynch
Syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) has also been
linked to ovarian cancer with a 12% lifetime risk (National Comprehensive Cancer Network,
2016). Because of the heterogeneity of inherited OVCA risk, testing clinics currently offer large
genetic sequencing panels which include all 24 genes known to associate with increased risk of
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breast, ovarian, and/or uterine cancers; ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHK2,
EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50,
RAD51C, RAD51D, SMARCA4, STK11, TP53.

1.4 Genetic Penetrance
The proportion of individuals carrying a variant (allele) of a gene that also express the
trait associated with that variant is referred to as penetrance. The degree of penetrance for
disease associated genetic loci varies greatly. Some mutations have complete penetrance,
meaning all individuals with the mutation have or will develop the disease (e.g Cystic Fibrosis,
Huntington’s disease). Most cancer-associated risk loci have incomplete penetrance, and many
carriers of the risk mutation may never develop cancer. BRCA1 is the most highly penetrant
gene in hereditary breast and ovarian cancer syndrome with an 80% lifetime risk of breast cancer
and up to a 50% lifetime risk of OVCA (Risch et al., 2001; Claus et al., 1996; Hereditary Breast
and Ovarian Cancer | Cancer.Net, 2017). Because clinical decisions such as prophylactic surgery
and chemo-preventative therapies are made based on risk assessment, accurate penetrance
estimates of cancer-associated loci is invaluable. Currently, genes known to be mutated in
hereditary cancer syndromes are referred to as having high, moderate, or low penetrance (Table
1, Stanislaw C., 2016). Unfortunately, penetrance is particularly difficult to determine for many
cancer-associated risk loci as pathogenic variants in these highly conserved genes tend to be rare.
In addition, environmental factors as well as other genetic and epigenetic alterations can
contribute, meaning penetrance can vary based on the carrier. Therefore, germline mutations in
cancer-associated genes are often described as having an unknown penetrance.
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PENETRANCE
High

GENE

BRCA1
BRCA2
APC
PTEN
TP53
MLH1
MSH2
MSH2
PMS2
STK11
CDH1
MUTHY
Moderate
ATM
CHEK2
PALB2
Low/unknown RAD50
RAD51C
RAD51D
BRIP1
BARD1
POLE
POLD1

CANCER RISK and GUIDELINES FOR
CLINICAL MANAGEMENT
Strong evidence for increased risk with
well-defined risk profiles, prophylactic
surgery or other preventative measures
advised

Moderate evidence for increased risk of
certain cancers, increased surveillance
advised
Varied evidence with clinical management
based on personal and family history

Table 1. Penetrance varies by gene and is often unknown. Table adapted from “Genetic
evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing”
Stanislaw C., 2016.
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1.5 BRCA1 and BRCA2
Both BRCA1 (breast cancer type one susceptibility) and BRCA2 (breast cancer type two
susceptibility) are tumor suppressor genes necessary for genomic stability.

Carriers of a

pathogenic mutation in either gene are at a greatly increased risk of multiple types of cancer,
most notably breast and ovarian. These two genes account for 5 to 10% of all OVCA cases
(Ramus and Gayther, 2009). In the general population, approximately 1 in 400 people have a
BRCA1/2 mutation that leads in increased cancer risk (PDQ Cancer Genetics Editorial Board
2002).

The prevalence of BRCA1/2 pathogenic mutations is particularly high for certain

ethnicities, specifically among Ashkenazi Jews where 1 in 40 are carriers of pathogenic founder
mutations (Robles-Díaz et al., 2004). Both genes have been well characterized and are involved
in numerous cellular processes important for genomic stability.
BRCA1 encodes for an E3 ubiquitin-protein ligase that facilitates a diverse range of
cellular processes including DNA damage repair, cell cycle control, apoptosis, transcriptional
regulation and embryonic development (W. Wu et al., 2008). BRCA1 interacts with numerous
proteins by taking part of large complexes required for these pathways. For instance, BRCA1
has been shown to interact with RNA polymerase II for regulation of p21 in response to DNA
damage (Moisan and Gaudreau, 2006), is involved in the MRE11-RAD50-NBS1 (MRN)
complex (L. Chen et al., 2008), as well as binds BRCA2 and RAD51 for homology directed
repair of double stranded DNA breaks (J. J. Chen et al., 1999). BRCA1 has also been shown to
regulate chromatin remodeling via the SWI/SNF complex (Bochar et al., 2000) and ubiquitinates
RBBP8 for CHK1 mediated G2/M cell cycle control (Yarden et al., 2012).
Similarly, BRCA2 is also involved in numerous cellular processes required for genomic
stability. These biological processes include DNA repair, cell division, histone acetylation, and
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replication fork maintenance. BRCA2 selectively binds to ssDNA and mediates HRR by aiding
in RAD51 ssDNA assembly and stabilization. This enables RAD51 to displace replication
protein-A (RPA) which binds single strand DNA (ssDNA) during the initial steps of DNA repair
(J. J. Chen et al., 1999). BRCA2 forms a complex with PALB2 to direct the localization of
POLH to collapsed replication forks (Buisson et al. 2014). In addition, this interaction is part of
a complex including RAD51C and involved in DNA repair by HRR (Sy et al., 2009). BRCA2
also regulates centrosome duplication via NPM1 (H. F. Wang et al., 2011). The BRCA2 protein
likely has additional functions yet to be verified. For example, it is suspected to play a role in S
phase checkpoint activation (Yoshida and Miki, 2004) and prevent R-loop DNA damage
incurred through the transcription process (Bhatia et al., 2014).

1.6 Missing heritability
For complex traits such as susceptibility to cancer it is possible to establish an estimate of
how much of the phenotypic variance is due to genetic inheritance. One classic means of
determining the heritability of a trait is through twin studies that measure the similarity of a trait
between monozygotic twins as compared to dizygotic twins. Monozygotic twins are derived
from a single fertilized egg and thus share the same genetic material while dizygotic twins,
formed from separate eggs, share about half of their genes. Because both sets of twins share the
same environment, at least in childhood, this approach controls for much of the environmental
contribution to cancer risk. If monozygotic twins resemble each other more than dizygotic twins
for a particular trait, then the heritability of that trait is estimated as twice the observed
difference.
Using this approach, a high amount of heritability has been observed in various types of
cancers, including melanoma (58%), prostate (57%), ovary (39%), and breast (31%) amongst
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others (Mucci et al., 2016). However, as with many multifactorial diseases, there is a gap in our
knowledge of the genetics underlying the predisposition. Often, the known genetic variation
attributed to a disease do not account for its total estimated heritability. This is referred to as ‘the
missing heritability issue’. For certain diseases, this unexplained heritability often limits how
informative genetic testing can be. Specifically, while ovarian cancer is demonstrated to have a
strong genetic component, the known risk loci cannot account for the majority of the familial
risk. Therefore, many women with compelling personal and or family histories regularly test
negative for the currently described susceptibility loci (Stafford et al., 2017).

1.7 Variants of unknown significance
Rare and private mutations are likely to account for much of the missing heritability in
ovarian cancer. This hypothesis is supported by the fact that many women who undergo genetic
testing are found to have a “variant of unknown significance” (VUS) (Stafford et al., 2017;
Towler et al., 2013; Domchek and Weber, 2008). The term “VUS” is used to describe a rarely
seen mutation, unannotated in its functional consequence on the protein or disease risk.
Assessing these variants is crucial for accurate risk assessment, prevention and targeted therapy.
Yet we currently lack a means to functionally validate private mutations in a clinical setting
(Towler et al., 2013). The American College of Medical Genetics and Genomics (ACMG)
provides detailed guidance as to the interpretation of genomic variants (Richards et al., 2015)
(Table 2). However, in the case of a missense change, it is difficult to obtain strong evidence for
pathogenicity, especially when rare. Therefore, the vast majority of compelling sequence
changes remains annotated as having only moderate evidence as to its pathogenicity.
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ACMG Evidence for Pathogenicity:
VERY STRONG

•

Loss of function variant in a cancer-associated gene

STRONG

•

Functional assay supportive of damaging effect

•

Increased prevalence in cases versus controls (O.R. >5)

•

Co-segregation with disease in multiple affected family members

•

In a mutational hot spot or well-established functional domain

•

Extremely low frequency or absent from ExAC, 1000 genomes

•

In-frame deletions/insertions

•

Co-segregation with disease in multiple affected family members

•

Multiple lines of computational evidence

MODERATE

Table 2. ACMG Evidence for Pathogenicity. Simplified and adapted from “Standards and
guidelines for the interpretation of sequence variants: a joint consensus recommendation of the
American College of Medical Genetics and Genomics and the Association for Molecular
Pathology”
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1.8 Implicating novel risk loci
When a trait or disease is suspected to be inherited, there are various approaches that can
be employed to identify the genes and variants responsible. One approach is through linkage
analysis, a hypothesis-neutral means to find segments of DNA which all affected persons of a
family share but the healthy relatives do not have. This is possible because genetic variants that
are close in proximity tend to be inherited together. The analysis begins with genotyping genetic
“markers” (highly variable regions of the DNA) on each chromosome for both affected and
unaffected individuals of a family. Once a region is identified as shared between and unique to
those affected, additional markers are added to further narrow the search within this region until
a specific gene and genetic variant is implicated.

This method is most appropriate when

attempting to map monogenic disease mutations and requires large families.
For complex traits and disease predisposition, a better approach to implicating genetic
variants is through association, such as a Genome Wide Association Study (GWAS). These
studies look for genomic variants that are statistically more prevalent in cases versus controls by
genotyping across the entire genomes of hundreds or thousands of individuals both with and
without the trait/disease of interest. GWA studies rely heavily on the “common disease, common
variant” (CDCV) assumption and are typically designed to exclude SNPs with a MAF < 5%
(Visscher et al., 2012). They lack the statistical power necessary to detect rare variants, which
are more likely to have a high effect. Therefore, GWA studies are best for implicating common
and low risk alleles that are not clinically actionable.
High-throughput sequencing using next generation technology allows for a more efficient
and unbiased approach in the discovery of novel cancer predisposition loci and has helped to
determine the frequency of germline mutations in HBOC. However, because of the rarity of
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ovarian cancer, large cohorts are obtained by recruiting participants that are not selected based
on family history. This means that, in large studies, most of the underlying etiology is sporadic,
and the majority of the causal variants uncovered are in BRCA1 and BRCA2, genes with already
well-established roles in OVCA.

For example, a recent publication reports the results of

sequencing 1915 patients with OVCA and found that of these cases, 347 (18%) carried
pathogenic germline mutations in genes associated with OC risk, 80% of which were in BRCA1
and BRCA2 (Norquist et al., 2015). Because patients were not selected for age or family history,
the vast majority of cases in this cohort are sporadic and not due to an underlying inherited risk.
This type of study, while impressive in size, is limited to estimating the prevalence of known
pathogenic mutations in the study population.
Hereditary OVCA is a rare disease with a high degree of genetic heterogeneity.
Therefore, despite the fact that any women with a diagnosis of OVCA is considered at risk of
possible germline risk, the best study design for identifying novel putative risk loci includes a
much stricter selection of patients. The most appropriate study sample would include only
OVCA patients with a suspicious family history indicating genetic inheritance of risk and would
exclude those with known pathogenic variants (Stafford et al., 2017).

Candidate risk loci

identified by the whole exome/genome sequencing of this sample would then be assessed by
both bioinformatics and functional analysis.

1.9 Gene panel vs whole exome sequencing for diagnostic purposes
Because of the immense heterogeneity of inherited cancer risk, current testing is
performed by analyzing a panel of associated risk genes to increase the chance of finding a
causal genetic variant. However, despite the introduction of larger and more inclusive gene
panels, issues of low diagnostic yield remain, and inconclusive results have brought an additional
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burden of stress on clinicians, patients, and relatives. Our knowledge regarding inherited cancer
risk is still very incomplete.

Therefore, testing panels are frequently being updated and

subsequently outdated and many who question the utility of panels favor a more practical whole
genome/exome approach by which genes can be analyzed post hoc without the need for
additional testing. The future of genetic testing seems poised for this approach, but hesitation
remains for various reasons.
One valid argument against employing exome sequencing in place of panel testing is that
it would sacrifice quality for quantity. High quality variant calls are necessary for accurate
clinical genetic diagnosis and whole exome sequencing (WES) is not ideal for detection of
variants in regions high in GC content, with many repeats, or with homology to other areas of the
genome (Sekhar et al., 2014). In contrast, panel testing focuses on a small number of genes
allowing for the luxury of more coverage, greater read depth, and thus higher quality variant
calls. Therefore, panels are traditionally believed to have superior detection of pathogenic
variants and thus a better diagnostic yield.

However, as our technology advances and

bioinformatic pipelines for variant calling improves, the quality of WES data will inevitably
reach comparable clinical sensitivity if it has not yet already. A recent study assessing the
coverage in 100 samples demonstrated that 99.7% of pathogenic variants were detectable by
WES at clinical sensitivity, and all had at least some coverage on exome sequencing (Laduca et
al., 2017). Another study compared the diagnostic performance of WES to two panels, TruSight
Cancer (94 genes) and another custom panel of 122 genes and identified a similar number of
variant calls (amongst shared genes) despite greater average read depth in panels (Feliubadaló et
al., 2017).
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Another important consideration besides call quality is cost.

However, the cost

discrepancy between WES and panels is narrowing and the long-term benefits of exome
sequencing may, in some cases, outweigh the difference. While sequencing exomes is more
expensive than sequencing panels, they provide additional patient data regarding genes that may
one day be clinically relevant and is accessible without the need for retesting. Panels can quickly
become outdated with each novel gene discovery and insurance will often only cover genetic
testing once.
Yet another valid concern for molecular diagnostic labs is testing turn-around time.
Many smaller labs may not be set up for WES on so many samples and sometimes immediate
clinical decisions are based on mutational status. Therefore, when to choose exome sequencing
over panel testing should be made on a case by case basis. Currently, as a first step into this new
era, WES may only be necessary in cases suspected to have inherited risk. For instance, NCCN
guidelines stipulate that women diagnosed with ovarian cancer are eligible for genetic testing
regardless of family history (“National Comprehensive Cancer Network. Panel Members
Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 1), 2018). While panel
testing is likely sufficient for most cases, those patients with a family history of breast or ovarian
cancer may benefit more from whole exome sequencing.

1.10 DNA repair and genomic integrity
The integrity of an organism’s genetic material is essential to its survival. However, our
DNA is constantly being damaged during the process of cellular metabolism as well as by
external environmental assaults such as radiation.

Consequently, all forms of life have

developed the ability to identify and repair these genomic lesions. While there exist many types
of DNA lesions, the most harmful is the double strand break (DSB). DSBs occur due to
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exposure to ionizing radiation (IR), various chemotherapeutic reagents, reactive oxygen species
(ROS) generated by cellular metabolic processes and in certain circumstances during DNA
replication (Mehta and Haber, 2014).

DSBs that go unrepaired can lead to a deletion,

amplification or even translocation of genetic material, potentially at a locus encoding for a
tumor suppressor or oncogene.

Therefore, effective repair of DSBs by either homologous

recombination repair (HRR) or non-homologous end joining (NHEJ) is crucial to avoid
tumorigenesis.
1.10.1 Homologous recombination repair
Homologous recombination repair (HRR) is a highly conserved and non-error prone
process that corrects DSBs using the sister chromatid as a template for gene conversion (Figure
3). Therefore, this mechanism can only be employed during G2 and S phase of the cell cycle,
when a homologue is available. Shortly after the double strand lesion occurs, HRR is initiated
by the phosphorylation of H2AX at Ser139 by ATM or ATR (Helt et al., 2005; Rogakou et al.,
1998). Phospho-H2AX (γH2AX) recruits various proteins to the damaged DNA, most notably
MRE11, RAD50 and NBS1 which form the MRN complex. This complex binds the broken ends
of the DNA for stability, likely preventing additional breakage in addition to initiating DNA
strand resection by endonuclease MRE11 (Lamarche, Orazio, and Weitzman., 2010).

The

resection creates single-stranded DNA (ssDNA) which is stabilized by Replication Protein A
(RPA) and acts as a probe in the search for a homologous sequence. Next, the broken strand
invades the sister chromatid through the action of RAD51, which replaces the RPA through the
action of BRCA2 (Buisson et al.. 2010). RAD51 then replaces RPA and forms filaments on the
DNA necessary for the strand exchange between homologous sequences (Buisson et al. 2010).
Synthesis of the missing DNA segment is filled in by replication machinery PCNA and
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polymerase δ and ε (Sneeden et al., 2013). Finally, the connected segments of the two DNA
molecules (Holliday junction) are resolved by nucleases.
1.10.2 Non-homologous end joining
Another pathway for DSB repair is Non-Homologous End Joining (NHEJ). During this
process, breaks in DNA are corrected by a direct ligation of the blunt ends and thus do not
require a homologue to serve as a template. While this mechanism is more error prone, it is the
most reliable mechanism for DSB repair in post-mitotic cells. NHEJ involves three basic steps:
DNA DSB damage recognition, processing of break ends, and strand ligation (Figure 3). In
NHEJ, DSBs are quickly recognized by heterodimer KU70/KU86 (KU80) which act to both
protect the strand ends from degradation as well as recruit DNA-PKcs, the catalytic subunit of
DNA dependent protein kinase (Jin and Weaver, 1997). End processing may occur before
ligation and may involve several enzymes including a nuclease (ARTEMIS), polymerases,
polynucleotide kinase/phosphatase (PNKP), and Aprataxin (APTX) among others (Povirk,
2012). For ligation of the processed break ends, both DNA ligase IV and XRCC4 are recruited
and activated via phosphorylation by DNA-PKcs (Povirk, 2012).
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Figure 3. Schematic illustration of the repair of a DNA DSB by homologous recombination
repair

(HRR)

and

non-homologous

end

joining

(NHEJ).

Image

Source:

https://www.intechopen.com/books/new-research-directions-in-dna-repair/radiosensitizationstrategies-through-modification-of-dna-double-strand-break-repair. Permission of image use
granted by Dr. Yoshihisa Matsumoto, Tokyo Institute of Technology.
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1.11 Targeted therapy in clinical cancer care
Our greater understanding of the molecular genetics underlying tumorigenesis has led to
a whole new field of precision medicine in which therapies are developed to target specific
“drivers” or deficiencies that encourage cancer progression. What initiates or “drives” the
process of tumorigenesis and metastasis differs by cancer subtype and even by individual tumor.
Tumor sequencing has thus become a routine practice in clinical cancer care to inform
therapeutic decisions. For instance, the most common driver of tumorigenesis in breast and
ovarian cancer is genomic instability due to inefficient DNA repair by homologous
recombination (Spring and Perspect 2015; van Gent and Kanaar 2016). Platinum-based agents,
the first-line therapy for these tumors, exploit this deficiency by causing DSBs vis intra and
interstrand DNA crosslinking (Ph and Andrea, 2016). Cancer cells are most sensitive to this
drug as they lack the ability to repair these breaks and damage will accumulate leading to
eventual cell death.
Another targeted therapy often used in conjunction with platinum in breast and ovarian
cancer is polyADP-ribose polymerase (PARP) inhibitors (PARPi). The PARP family of proteins
is involved in a form of ssDNA repair known as Base Excision Repair (BER). Cancer cells
deficient in other DNA repair mechanisms are more dependent on the PARP proteins. By
inhibiting this pathway, the cell loses its ability to repair DNA leading to synthetic lethality.
Tumor cells with mutant BRCA1 and/or BRCA2 have demonstrated to be up to 1000 times more
sensitive to PARPi as compared to WT cells (Farmer et al., 2005; Bryant et al., 2005). In clinical
trials, the use of PARPi has shown to improve progression-free survival when added to the
treatment of women with breast or ovarian cancer responsive to platinum (Robson et al. 2017;
Ledermann, 2016; Evans and Matulonis, 2017). More recently, investigators have identified an
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additional mechanism of action for PARPi. PARP proteins were found to localize at DNA
damage sites and become trapped on the DNA when bound to an inhibitor, blocking DNA
replication, and causing cell toxicity (Lord and Ashworth, 2017).
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CHAPTER 2: MATERIALS AND METHODS
2.1 Sample ascertainment and description
Study samples were acquired through the Karmanos Cancer Institute Genetic Registry
(KCIGR), an IRB approved biospecimen repository comprising females with a personal or
family history of breast and/or ovarian cancer and at elevated risk of harboring a BRCA1/2
mutation. Over 800 DNA samples from breast and/or ovarian cancer patients were collected
spanning the years of 1999-2013, when HBOC genetic screening was limited to BRCA1/2 and
risk assessment was performed using BRACAPRO and Myriad II, which were the standard of
care during the duration of accrual. BRCAPRO is a computer-based Bayesian probability model
that uses breast and/or ovarian cancer family history to determine the probability that a BRCA1
or BRCA2 mutation accounts for the pattern of these cancers in the family (Parmigiani, Berry,
and Aguilar, 1998). Key attributes of consideration include the population prevalence of BRCA
mutations, age-specific penetrance, and Ashkenazi Jewish heritage.

Myriad II is a set of

prevalence tables categorized by ethnic ancestry (Ashkenazi Jewish or non-Ashkenazi Jewish),
breast cancer age of onset (age ≤50 years), and the presence of ovarian cancer, in the patient
and/or first- or second-degree relatives. Myriad II is based on historical test data from the
Myriad Genetic Laboratories clinical testing service (Frank, 1999).
Through the KCIGR biospecimen repository, we obtained 89 DNA samples from high
risk Caucasian women with a personal history of OVCA. Participants were either confirmed
BRCA1/2 mutation carriers or BRCA1/2 negative after full gene sequencing, BART
(BRCAnalysis rearrangement test) or testing for the three common Ashkenazi Jewish mutations
(Myriad Genetics Laboratories, Salt Lake City, Utah).

Participants testing positive for

pathogenic BRCA1/2 germline mutations were excluded from the study sample. The final
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sample consisted of 48 BRCA1/2 mutation negative Caucasian OVCA patients from 47 families
(one mother-daughter pair). All subjects provided written informed consent for the collection of
blood samples and access to medical records.

The protocol (HIC#024199MP2F(5R)) was

approved following Full Board Review by the Human Investigation Committee at Wayne State
University, Detroit, Michigan.
Information regarding tumor histology, tumor grade, age of diagnosis, and family history
of study sample is summarized in Table 3. Tumor histology from study sample patients included
serous (n=26), endometrioid carcinoma (n=5), mixed (n=4) adenocarcinoma (n=2), mucinous
(n=1), clear cell (n=1), and undefined (n=9).

Tumor grade included grade 2 (moderately

differentiated, n=6), grade 3 (poorly differentiated, n=24), and grade 1 (well differentiated, n=1).
Ovarian cancer was the primary diagnosis for 43 patients, while four had a primary diagnosis of
breast cancer and one of cervical cancer followed by a secondary OVCA diagnosis. Of those
with a primary OVCA diagnosis, six had a secondary cancer diagnosis: two breast, two colon,
one uterine and one melanoma.
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Mean Age at Diagnosis
Histology

52.8 (yrs.)
n=

25-81 (range)
%

Serous
Endometrioid
Mixed
Adenocarcinoma, NOS
Clear Cell
Mucinous
Unknown

26
5
4
2
1
1
9
n=
8
5
23
3
9
n=

54
10
8
4
2
2
19
%
17
10
48
6
19
%

1
6
24
17
n=
15
12
31
14
47

2
13
50
35
%
31
25
65
29
98

Stage
I
II
III
IV
Unknown
Grade
Grade 1- well differentiated
Grade 2- moderate
Grade 3- poor
Unknown

Personal and Family History
personal BC/OVCA diagnosis < 50 yrs. of age
personal second primary cancer diagnosis
personal/family history of BC
family history of OVCA
family history of epithelial cancer

Table 3. Tumor histology, tumor grade, age of diagnosis and family history of study
sample
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2.2 Whole exome sequencing
DNA from peripheral blood samples was isolated by the Karmanos Applied Genomics
Technology Center, Detroit, MI using QIAamp DNA mini kit (Qiagen) and whole exome
sequencing (WES) was performed using Nextera Rapid Capture Kit. Samples were
demultiplexed using Illumina’s CASAVA 1.8.2 software (Kumar et al., 2014). Read quality was
assessed

with

FastQC

(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/2)

and

alignment to the human reference genome (hg19) (Lander et al., 2001) was performed using
Burrows Wheeler Aligner (BWA) (Li and Durbin, 2009). PCR duplicates were removed using
Samtools, (Li et al., 2009) and subsequent local realignment, Qscore recalibration, variant calling
and filtering was performed using Genome Analysis Toolkit (GATK) (DePristo et al., 2011)
Unified Genotyper and Haplotype Caller. SNPs were filtered out if: 1). Four or more alignments
have mapping quality = 0 and the number of alignments that mapped ambiguously were more
than 1/10 of all alignments for the given SNP. 2). SNP is represented by less than 5 reads 3).
SNP quality is below 50 4. QD score (variant confidence) is below 1.5. Variant files were
constructed

using

Genome

Trax

BIOBASE

biological

databases

analysis

software

(http://www.biobase-international.com) and annotated with Illumina BaseSpace VariantStudio
application v2.2.4 (www.illumina.com) and snpEff (Cingolani et al., 2012).

2.3 Panel and candidate genes analyzed
Genes analyzed for potential risk variants included those currently featured on HBOC
genetic testing panels by Ambry OvaNext and Myriad MyRisk: BRCA1, BRCA2, MLH1, MSH2,
MSH6, PMS2, EPCAM, APC, MUTYH, CDKN2A, CDK4, TP53, PTEN, STK11, CDH1,
BMPR1A, SMAD4, PALB2, CHK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D, in addition
to 155 non-panel candidate genes important to DNA damage response or cell cycle regulation
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and 64 genes listed as having disease causing mutations associated with OVCA in HGMD. A
full list of non- panel candidate genes analyzed is provided in Table 4.
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Table 4. Non-Panel genes analyzed for high impact variants Genes were chosen based on
their involvement in either DNA repair cell cycle control, or due to being listed as having
“disease causing mutations” (DM) associated with OVCA in HGMD.
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2.4 In silico SNP assessment
In silico variant assessment of single nucleotide polymorphisms (SNPs) was performed
using online available bioinformatics tools, HGMD (Stenson et al., 2003), dbSNP (Sherry et al.,
2001), ExAC (http://exac.broadinstitute.org), SIFT (Ng, 2003) and PolyPhen (Gnad et al.,
2013). Variants were stringently filtered to include only exonic SNPs most likely to have a
moderate to high effect impact on protein function (frameshift, nonsense, and missense) while
also rare, (<0.02 MAF ExAC; European, non-Finnish) and predicted to be damaging by SIFT
and/or PolyPhen, which take into consideration parameters such as amino acid substitution and
evolutionary conservation. Variants passing these criteria were confirmed by forward and reverse
strand Sanger sequence (GENEWIZ, South Plainfield, NJ) unless otherwise specified.
Additional bioinformatic resources were consulted to further describe variants including: dbSNP,
UCSC Genome browser, and the Human gene mutation data base (HGMD) which lists variant
risk predictions from Mutation predictor risk assessment, Likely hood ratio test for functional
prediction (LRT), Mutation taster prediction, and Genomic Evolutionary Rate Profiling (GERP).

2.5 Next generation sequencing validation
Next generation sequencing and other high throughput methodologies are fast and
efficient at the cost of accuracy. Therefore, all variants of interest called by WES were validated
by Sanger sequencing. Using the primers listed in Table 5, 400-700 bp DNA products, which
included the variant of interest were amplified by PCR (Polymerase Chain Reaction) followed by
agarose gel electrophoresis to check for amplification and possible contamination. The amplified
DNA fragments were then purified by spin column and quantified before being sent out to
GENEWIZ for Sanger sequencing.
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2.5.1 Primer design
Primers for PCR amplification and targeted sequencing were designed using Primer3Plus
(http://www.bioinformatics.nl/cgi- bin/primer3plus/primer3plus.cgi), which includes information
regarding primer binding specificity, GC percentage, and melting temperature (Table 5).
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Gene

dbSNP ID

Variant

Forward Sequencing Primer

Reverse Sequencing Primer
TTTTTCATCATATAATCCCTATGCTC

ATM

N/A

c.2503_2507del

AAGAAGAACTTTCATTCTCAGAAGTAG

ATM

N/A

c.5697_5698insA

TGGTGTACTTGATAGGCATTTGA

TCTGAGCTTTTCCACACTGC

ATM

rs1800054

c.146C>G

GAGCTACAGAACGAAAGGTAGTAAA

TTTCCTCTAATCTGAAGTCTTGTGAA

ATM

rs138327406

c.4388T>G

ATCAGAAAATTCTTCTTGCCATA

CAGGAGGTTGAGGATGCAGT

ATM

rs28904919

c.998C>T

TTTTGTGGGAGCTAGCAGTG

GGTGGCTCATGCCTGTAATC

ATM

rs56009889

c.6919C>T

GTGGGGAGATGTCATGCAG

GGGACACCAATGCCTCTACTT

ATM

rs35203200

c.7618G>A

CCTCAGATAAGAAAAGA

TGCAGTGGGTAGAGCGTG

AXIN1

rs143974067

c.1018G>A

TTCCTGAAGACAAAGCCCAG

GTCACTAACATGCCCTGCTT
CAGAGGCAACGAAACTGGACTCA

BRCA1

rs4986852

c.3119G>A

TCCCATAGGCTGTTCTAAGTTATCTG

BRCA1

rs1800744

c.4535G>T

TTGAGCTATTTTTCTAAAGTGGGCTTA

AGGCAACATGAATCCAGACTTCTAG

BRCA2

rs80358479

c.1889C>T

GCCTCTGAAAGTGGACTGGA

GCAGGCATGACAGAGAATCA
CAATGACTGATTTTTACCAAGAGTGCAAA

BRCA2

rs28897747

c.8149G>T

TAAAACTAGTAGTGCAGATACCCAAAAAGTG

BRCA2

rs11571747

c.8567A>C

TGGAGGAAATGTTGGTTGTGTTGA

CCTTCATGTTCTTCAAATTCCTCCTGA

BRCA2

rs11571833

c.9976A>T

CACCTGTCTCAGCCCAGATGAC

AGTTGTAATTGTGTCCTGCTT

BUB1B

rs28989188

c.1227A>C

TTCCCCACTTTACGCTTTTG

ACCATAGAAGGCAGCAGTGG

CHK1

N/A

c.1564-1565insA

TGAAGTGCCTCTAAAGTTTCCA

TGTTCACACAATGATGAAACCA

CHK2

rs587780185

c.565A>G

ATCACAGTGGCAATGGAACC

CTCCCAAAGTGCTGGGATTA

ERCC6

rs201486862

c.2137A>G

TCGGATCATTCTGTCTGGCT

ATGAGCCTGGCCATCTTTCT

FANCM

rs144567652

c.5713C>T

TCTAGCACTTCAGGGGCATC

TGAAGTGAGCTGTTAGCCATCC

ACCTCACAATGCCATTCCA

AAGCTGAAAGGCTGGTCAAG

HMMR

rs146791423

c.1054G>T

MCM4

N/A

c.1610-1611del

GCGGGACAAGGAAGGATTTT

CATGTTCACGGTGGAGAAGG

MSH6

rs63751005

c.620T>C

TGAACTGGGGCTGGTATTCA

AAGCACACACCATATGCACG

MUTYH

rs34612342

c.494A>G

GTCTCTTTCTGCCTGCCTGT

CTACGTTGCCATCCACCAC

MUTYH

rs36053993

c.1145G>A

AACACTGGACAGTGCCACCT

AAGGGTCAAGGGGTTCAAAT

NBN

rs61754966

c.511A>G

CAACAAAGAAATTTGGGGAAC

GCAGTGACCAAAGACCGACT

PALB2

rs45551636

c.2993G>A

TTTGGCTTAGGGCATTGTTT

GACATGTCTGGCTTCCACCT

PALB2

rs45532440

c.2014G>C

CCTGATGAAGACTTTGGACCTC

TAAGATGGGGAAAGCAGGTG

PALB2

rs200283306

c.3508C>T

TCTGTCTGGACATAAACAAGCAA

ACTCTCAGCGTGGGTGTGAT

PALB2

rs45478192

c.2816T>G

ATCTTTCAGATTCTTTCAAGACTCAAGCC

CTGGATTAAACAAAAATGAAACAACCAAGC

PALB2

rs45494092

c.1010T>C

ATTTCACCAGGGCGACTACA

TTGACTCAAAGGGCTCCACT

PALLD

rs138897963

c.909A>T

ACCTCAGCAGATGTTGTGTC

ATGGGTGCCTAAATGTCGGA
GTTGCAGTGAGCTGAGATCG

PMS2

rs200513014

c.1004A>G

CAGTGGCTGCTGACTGACAT

POLK

N/A

c.1336del

TGAATAGGCTATGGGAGAAAGAA

GGCATTTATTGCAGGGAGTG

POLQ

rs148626322

c.7537C>T

TCCCAAAGAGGGTTACAGGA

AGGCTGAGCGTCAAGCTATC
TTGGGAGTTCTGAGCAGTGTT

RAD1

N/A

c.1154del

CGGCCACCTTTAGACTCTTG

RAD51D

rs587781756

c.511C>T

CCTGCAGCAAAACGTCCTAT

AGTAGGACACCTGCCCACAG

RAD51D

rs387906843

c.616C>T

ACCACTGTGACAACTGACCA

AGTAGGACACCTGCCCACAG

RAD52

rs4987208

c.1245T>G

TAGCAGGAAGCGGAAACG

ACTGCAGTGGGCTCTCAGTC

RAD52

rs4987207

c.806C>A

TCCAGTTCCTCTTTGGTCCT

AGGATCTCCCCTTAATTTTTGTG

REC8

N/A

c.1622G>A

GACCTTCCCCCACTACACAG

TGGGGATGGGAGAAGTAGAA

RECQL

rs150889040

c.962G>A

GAAGCTCTGACCATCCCTGA

CAACAGTTGCCACTACTACCTG

TP53I3

rs145078765

c.755C>G

TCTGAAATCGGGTTCCCTCT

AGGCCTCATAAATGGTGAACTT

Table 5. Primers for the amplification and sequencing of indicated genomic loci
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2.5.2 PCR amplification
Polymerase chain reaction (PCR) is a frequently used method for the exponential
amplification of short sequences of DNA. PCR requires the use of primers (Table 5) that a
thermo-stable DNA polymerase extends to replicate the target (HotStarTaq Plus DNA
Polymerase, QIAGEN Fast Cycling PCR KitCat No./ID: 203743). Each round of amplification
requires a three-stage temperature fluctuation process to facilitate the reaction (see PCR Protocol
below).

For ample product yield, the thermocycler (Mastercycler, Eppendorf, Hamburg,

Germany) was set for 36 rounds of amplification.
PCR reaction set up

20 μl

Qiagen Master Mix =

10 μl

Primer (forward) =

2 μl

Primer (reverse) =

2 μl

DNA (25ng/μl) =

2 μl

sterile dH20

4 μl

PCR protocol:
1. Original denaturation: The DNA was heated at 95°C for 5 minutes to denature.
PCR Cycle begins:
2. Denaturation: 96°C for 5 seconds
3. Primer Annealing: 55-62 °C (optimized for specific primer pair efficiency)
4. Elongation: 68 °C for 15 seconds
PCR Cycle ends (new cycle begins)
5. Final elongation: After the last PCR cycle (36 in total), the reaction was incubated at 72 °C for
2 minutes to ensure full extension of any remaining ssDNA.
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2.5.3 Agarose gel electrophoresis
Agarose gel electrophoresis is a simple method that separates DNA fragments by
molecular weight/size. DNA molecules carry a negative charge due to the phosphate backbone
and migrate towards the positively charged end of an electric field. For visualization, ethidium
bromide is incorporated into the gel as it intercalates between the bases of dsDNA and fluoresces
under UV light. The size of the DNA fragment determines the speed at which it migrates. The
larger the fragment, the slower it will migrate through the porous gel. Therefore, DNA product
size can be measured by comparison with a standardized ladder. This method is used for the
confirmation of PCR product and to identify possible contamination that occurred during the
amplification process.
Agarose Gel Electrophoresis Protocol: 1 g of agarose powder (Thermo Scientific,
Waltham, MA, Cat# R0491) was dissolved into 100 ml of TAE buffer by boiling. 15μl of
ethidium bromide was then mixed into the solution before allowing it to solidify in a gel forming
tray. Once solidified, the gel was placed onto an electrophoresis plate, and submerged in TAE
buffer. 2μl of loading dye (QIAGEN Fast Cycling PCR KitCat ID: 203743) was added to the
PCR product. 2μl of PCR product was loaded in each well. For PCR product size measurement,
2μl of a 100bp DNA ladder was also added. The gel was then given 45 minutes of a 400-mA
current at 80 volts, followed by visualization using a UV source (Fisher Biotech, Wembley,
Austrailia, Electrophoresis Systems).
2.5.4 Sanger sequencing
Sanger sequencing is a commonly employed method for the accurate sequencing of DNA
using chain-terminating (dideoxy) nucleotides incorporated by a DNA polymerase during invitro PCR amplification. Each nucleotide version, ddATP, ddTTP, ddCTP, ddGTP, is labeled
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with a unique fluorescent dye so that during replication, DNA fragments are randomly
terminated with the fluorescent label. The amplified products are then separated by Capillary
Array Electrophoresis (CAE), which detects fluorescently labeled fragments and provides an
ordered sequence of the fragments based on product length to be computationally assembled.
The Sanger method, developed in 1977 by Frederick Sanger, was once the most widely
employed sequencing technology. While high throughput sequencing (Next Generation
Sequencing) has become the current preferred methodology, Next-Gen results are often validated
using Sanger sequencing as it is considered more reliable.
Sanger Sequencing Preparation Protocol: PCR products were purified by spin column
(Qiagen QIAquick PCR Purification Kit Cat# 28104) and quantified by spectrophotometer
(NanoDrop 2000, Thermo Scientific).

PCR reactions were prepared before shipment to

GENEWIZ and trace files were visualized using SnapGene Viewer v3.3.3.
Sequence Reaction

15 μl

Primer =

5μl

DNA (25ng/μl) =

2μl

sterile dH20

8μl

2.6 Cell line assessment and cell culture
HeLa cells were used for all functional experimentation during this project. This cell line
was chosen based on various necessary criteria including having at least some wild type (WT)
p53 expression (Figure 4A), an intact homologous repair pathway, a doubling capacity of every
24 hours (Figure 4B) and epithelial in origin. While HeLa is a cervical cell line, it is often used
in cancer studies for these reasons. Although use of an ovarian cell line is ideal, most immortal
ovarian cell lines do not have WT p53 activity (Mullany et al., 2015; Fleury et al., 2015)
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meaning processes downstream of p53 such as DNA damage, cannot be assayed accurately.
Additionally, the issue of cell line misidentification is common with many “ovarian cell lines”
(Korch et al., 2012).

All cell lines considered for experimental purposes were sent for

authentication (Wayne State University at Applied Genomics Technology Center).

The C13

ovarian cell line obtained from an outside lab was confirmed to be ME-180 cervical cells. All
other cell lines were authenticated as being correctly labeled.
HeLa cells stably transfected with p.DR-GFP were a kind gift from Dr. Jeffery Parvin of
Ohio State University. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (HyClone, GE, Little Chalfont, United Kingdom
Cat# SH30396.03), NaHCO3 (3.7g/L) 1% penicillin strep (Gibco Life Technologies, Carlsbad,
CA Cat# 15140-122) and incubated at 37°C 5% CO2. For passaging, cells were harvested using
trypsin, and split 1:6. Freeze downs of aliquots were maintained in a freezing media of 10%
DMSO, 50% DMEM, 40% FBS and kept at -140°C.
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A

B

Figure 4. Cell line analysis
A. Western blot for p53 expression in cell lines. p53 expression observed in positive control
(LJT), ME-180 (originally thought to be C13 ovarian cell line and shown to be cervical of origin
during authentication) and HeLa. p53 expression was not detected in hTERT immortalized
ovarian cells (hTERT OV), SKOV3 cells or TP53-negative control MDAH041. Abnormal p53
expression was detected in T80 SV40-Transformed ovarian cells.

B. Microscopy images of

GFP activity as a proxy for intact HRR in ME-180, and HeLa (see section 2.8 Homologous
Recombination Repair Assay). Very little GFP activity was observed in T80 cells and none in
SKOV3 or hTERT immortalized ovarian cells.
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2.7 Protein detection and quantification
Western blot was employed to assay protein expression and quantification. First, cells
were lysed, and proteins solubilized using ice cold RIPA (Radio immunoprecipitation assay
buffer) supplemented with protease and phosphatase inhibitors.

Protein concentration was

determined by Bradford assay. Proteins were then reduced and denatured by adding 4x Laemmli
buffer plus β-mercaptoethanol to lysates (9:1 ratio respectively), in addition to boiling at 95°C
for 5 min using thermocycler. Lysates were stored at -80°C until use for SDS page (sodium
dodecyl sulfate polyacrylamide gel electrophoresis).
Next, 50-70μg of whole cell lysate was loaded into each well of a polyacrylamide gel and
separated by electrophoresis. Gel percentage varied by size of protein of interest. Stacking gels
were prepared at 5%. 7.5% separating gels were used for proteins above 100 kDa and 12% gels
for proteins below 100 kDa. Following separation, proteins were transferred from the
polyacrylamide gel to a nitrocellulose membrane by electrical current (250 -350 mA). Small
molecular weight proteins were transferred for approximately 1 hour at room temperature (RT),
large molecular weight proteins 3-4 hours RT or 18 hours overnight at 4°C.
Membranes were then blocked with 5% bovine serum albumin (BSA) in Tris Buffered
Saline with Tween 20 (TBST).

Next, membranes were incubated with protein specific

antibodies at RT for two hours, given three 10 min washings with TBST, incubated with
secondary antibody for 1 hr. RT, and followed by three more 10 min TBST washings. Images
were obtained by LI-COR Biosciences, Lincoln, NE, Odyssey Blot Imager and protein
expression was quantified using ImageJ software and normalized to appropriate loading control
(ACTIN for smaller proteins, VINCULIN for large molecular weight proteins).
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RIPA lysis buffer

80 ml

1 M Tris-HCL ph. 7.4

4 ml

1.5 M NaCl

8 ml

1% NP40

800 μl

5% Na-deoxycholate

4 ml

.4 M EDTA

200 μl

dH20

63 ml

The day of lysis, 10 μl of protease inhibitor cocktail (PIC), sodium pyrophosphate (NaPP),
sodium fluoride (NaF), sodium orthovanadate (NaV), and phenylmethane sulfonyl fluoride
(PMSF) was added to every ml of RIPA lysis buffer
SDS page stacking gel

5%

4x stacking buffer

1.25 ml

Acrylamide/Bis 40:32%

.5 ml

dH20

3.25 ml

10% APS

25μl

Temed

5 μl

SDS page separating gel

7.5% 12%

2x separating buffer

5 ml

Acrylamide/Bis 40:32%

2.5 ml 3 ml

dH20

2.5 ml 2 ml

10% APS

100 μl 100 μl

Temed

25 μl

5 ml

25 μl
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Transfer buffer: LMW <100kDA

HMW >100kDA

TRIS

6.06 g

6.06 g

Glycine

28.8 g

28.8 g

Methanol

400 ml

200 ml

dH20

1600 ml

1800 ml

SDS

-----

.01%

Antibodies for protein detection:
Protein

Cat#

Manufacturer

ATM

sc-377293

Santa Cruz Biotechnology, Dallas, TX

BRCA1

sc-6954

Santa Cruz Biotechnology, Dallas, TX

BRCA2

sc-28235

Santa Cruz Biotechnology, Dallas, TX

P53

AHO0152

Invitrogen, Carlsbad, CA

CHK1

sc-7898

Santa Cruz Biotechnology, Dallas, TX

CHK2

sc-9064

Santa Cruz Biotechnology, Dallas, TX

TP53I3

sc-16664

Santa Cruz Biotechnology, Dallas, TX

FANCM

AB97905

Abcam, Cambridge, United Kingdom

REC8

sc-15152

Santa Cruz Biotechnology, Dallas, TX

RAD1

sc-166495

Santa Cruz Biotechnology, Dallas, TX

RAD51D

sc-398819

Santa Cruz Biotechnology, Dallas, TX

HMMR

PA5-21105

Invitrogen, Carlsbad, CA

MCM4

sc-28317

Santa Cruz Biotechnology, Dallas, TX

VINCULIN

700062

Invitrogen, Carlsbad, CA

ACTIN

sc-1616

Santa Cruz Biotechnology, Dallas, TX
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2.8 Homologous recombination repair assay
The homologous recombination repair assay is a sensitive method developed to measure
Homologous Recombination Repair (HRR) pathway efficiency following double strand breaks
(DSB). HeLa cells were stably transfected with pDR-GFP (direct recombinase green fluorescent
protein) plasmid and selected with 1.5μg/ml puromycin. The pDR-GFP plasmid contains two
inactive GFP alleles; one is inactive due to the presence of an additional sequence that contains
the 18bp restriction enzyme recognition site for I-SceI, the other is inactive due to a truncating
mutation. When a second plasmid encoding the enzyme I-SceI is transiently transfected into
cells containing this plasmid, the I-SceI restriction site is cleaved creating a DSB. The break can
only be repaired by the cells’ own endogenous HRR pathway using the second inactive GFP
allele as a template. In the case of a working HRR pathway, this leads to the restoration and
activation of the first GFP allele (Figure 6A). Therefore, the amount of GFP following I-SceI
DSB induction proxies for the efficiency of the HRR pathway. This method can accurately assay
a gene’s involvement in the HRR pathway by measuring the amount of GFP observed after
siRNA knock down as compared to a scramble siRNA control.
HRR Assay Protocol: Cells were harvested with trypsin, counted using a hemocytometer
and reseeded at 40,000 into each well of a 24 well plate. The next day, media was replaced with
450 µl serum and antibiotic free media and cells were transfected with I-SceI and siRNA specific
to the gene of interest using Lipofectamine 3000 (Thermo Fisher, Waltham, MA, Cat#
L3000015) according to manufacturer’s protocol. As a negative control, cells were transfected
with p.cDNA3 empty vector in place of I-SceI to gauge background GFP signal. As a positive
control, cells were transfected with scramble siRNA plus I-SceI. Each condition was performed
in triplicate. Forty-eight hours post transient transfection of the I-SceI containing plasmid, cells
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were visualized for GFP signals using fluorescence microscopy (Olympus 1X71) followed by
harvesting and analysis by flow cytometry (BD FACSCanto II and BD FACS Diva Software
v8.0.1, BD Biosciences, San Jose, CA). Gating procedure was set to select singlets, live (DAPI)
and GFP (FITC) positive cells (Figure 6B). A t-test was employed to compare cells transfected
with a siRNA knockdown of a gene of interest to the siRNA scramble positive control and
adjusted for background GFP (negative control).
Gene

Cat#

Manufacturer

Scramble

1027310

Qiagen, Hilden, Germany

ATM

S100299299

Qiagen, Hilden, Germany

BRCA1

SC-29219

Santa Cruz, Dallas, TX

BRCA2

S102653434

Qiagen, Hilden, Germany

CHK1

S100287658

Qiagen, Hilden, Germany

CHK2

S102224264

Qiagen, Hilden, Germany

FANCM

S104158280

Qiagen, Hilden, Germany

HMMR

S102653196

Qiagen, Hilden, Germany

MCM4

S100300818

Qiagen, Hilden, Germany

RAD1

S102653462

Qiagen, Hilden, Germany

RAD51D

S100045094

Qiagen, Hilden, Germany

REC8

AM16708

Ambion (Invitrogen), Carlsbad, CA

TP53I3

S100069636

Qiagen, Hilden, Germany
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A.

B.

Figure 5. Homologous recombination assay A. Schematic of DSB induction during I-SceI
cleavage and GFP induction by HRR. B. Flow cytometry gating procedure for selection of GFP
positive cells.
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2.9 Clonogenic survival assay
The clonogenic survival assay tests the ability of a single cell to form a colony and is a
well-established method to determine the importance of a gene to cellular survival as well as to
test cell sensitivity to DNA damaging treatments such as ionizing radiation or chemotherapeutic
drugs. Certain drugs are of interest due to their ability to create double strand breaks in DNA.
Because DSBs are repaired using the HRR pathway, cells efficient in this pathway retain the
capacity to repair themselves and produce colonies after exposure, while those deficient in HRR
do not.

Therefore, clonogenic assays involving drug treatments that induce DSBs are an

excellent tool for identifying genes important to the HRR process, as well as for indicating which
chemotherapeutic drug may be most appropriate for targeted therapy considering the genomic
background of certain tumors.
Clonogenic survival assay protocol: Cells were plated (350,000) in 60-mm tissue culture
dishes and incubated overnight at 5% CO2 and 37°C. The next day cells were transfected with
siRNA using Oligofectamine (Invitrogen, Carlsbad, CA Cat# 12252-011) according to the
manufacturer’s protocol. 24 hours after transfection, cells were counted, and 100 to 300 cells
were reseeded in triplicate of a 6 well plate and placed back in incubator. The following day (48
hours post siRNA knock down) the media was replaced with serum free media containing a
DNA damaging reagent such as Cisplatin, Etoposide, Olaparib, or mock control for the duration
and drug concentration optimized for an IC50 (50% cell growth inhibition) in HeLa. Cells were
rinsed twice before adding back fresh media and incubated at 5% CO2 and 37°C for 1.5 weeks
until colonies had formed (>50 cells per colony).

For fixation and staining, medium was

removed, and cells washed PBS before adding add 2 ml of acidic acid fixation solution for 5
minutes followed by 2 ml 0.5% crystal violet solution for 2 hours at room temperature. Once the
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crystal violet was rinsed off, plates were air-dried at RT for up 24 hours. Colonies were counted
both by eye and with a colony counter (GELCOUNT, Oxford Optronix, Abingdon, UK). Plating
efficiency (PE) was calculated as the number of colonies formed divided by the number of cells
seeded x 100%. Survival after drug treatment was determined by calculating the number of
colonies formed divided by the number of cells seeded x 100%, adjusted for PE.

2.10 Statistical analysis of functional data
Statistical analyses of homologous recombination repair and clonogenic assays were
carried out using R statistical software (version 3.4.1). Prior to the analysis, we checked for and
did not find outliers (i.e., data points greater than 3 standard deviations from the mean for each
variable). We next investigated the distribution of replicates for each tested condition (reduction
in HRR efficiency, plating efficiency, and adjusted survival rate after drug treatment following
siRNA knockdown). First, we calculated Shapiro-Wilk’s tests, which tests the null hypothesis
that a sample distribution was drawn from a normally distributed population. Next, we assessed
skewness and kurtosis for each gene per condition. For small samples (n < 50), z-scores less than
1.96 for either skewness or kurtosis suggests a normal distribution14. We performed
approximately six replicates for each condition to reduce inflation of Type II error. The overall
pattern of results generated from the HRR and clonogenic assays indicated normal distributions
(detailed results available upon request). Paired sample t-tests were then conducted to identify
mean differences in the survival rates for each siRNA knock down condition and its respective
scramble siRNA control.
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CHAPTER 3: RESULTS PART I
3.1 Clinically actionable variants
We performed WES on blood DNA from 48 women with a personal history of OVCA
and determined to be at high risk for inheritance of a germline predisposition mutation, but with
no known deleterious mutations in BRCA1/BRCA2. In total, five clearly pathogenic loss of
function variants were identified (Table 6). Four were in genes currently featured on newer
comprehensive HBOC panels; two novel frameshift variants in ATM (c.2503_2507del and
c.5697_5698insA) and two truncating variants in RAD51D (rs587781756 p.Q171* and
rs387906843 p.R206*, as well as a pathogenic variant in a non-panel gene, FANCM
(rs144567652 p.R1931*) previously found to be strongly associated with hereditary risk of
breast cancer (Peterlongo et al., 2015). Pathogenic variants in genes with an associated cancer
risk are considered clinically actionable, meaning a medical intervention, or risk reduction
measures are available.
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Table 6. Clinically Actionable Variants
ID

Gene

Consequence

AA

dbSNP ID

Variant

MAF

OBS

OCF28-1

ATM

FRAMESHIFT

CATCTG>C

N/A

c.2503_2507del

N/A

1

OCL56

ATM

FRAMESHIFT

G>GA

N/A

c.5697_5698insA

N/A

1

OCJ19

FANCM

STOP

R1931*

rs144567652

c.5713C>T

0.0009

1

OCH26

RAD51D

STOP

Q171*

rs587781756

c.511C>T

N/A

1

OCK1

RAD51D

STOP

R206*

rs387906843

c.616C>T

0.0001

1

Table 6. Clinically Actionable Variants are those of high impact (frameshift or stop gain) in
genes already associated with either breast or ovarian cancer. AA= Amino acid change,
MAF= Minor allele frequency (ExAC, European non-Finnish) OBS= Number of times variant
was observed in sample. N/A= Not Available. All variants listed were confirmed by Sanger
DNA Sequencing.
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ATM (Ataxia Telangiectasia Mutated) codes for a protein kinase important for DNA
damage recognition and activation of substrates including p53, BRCA1, and other homologous
recombination repair factors. Homozygous mutations in ATM cause ataxia-telangiectasia, a rare
inherited autosomal recessive disorder which affects the immune and nervous systems and leads
to increased sensitivity to radiation and cancer susceptibility.

Although heterozygous

ATM mutation carriers do not have ataxia-telangiectasia, they have a 17-52% lifetime risk of
developing breast cancer (Broeks et al., 2000). However, despite association of ATM with
ovarian cancer in recent literature, carriers are not routinely counseled with this information as
exact risks are unknown. One patient with an ATM pathogenic variant in our sample (OCF28-1)
had a family history of liver, lung (n=2) and breast cancer, on the same parental side of the
family. The proband herself was first diagnosed with breast cancer at the age of 48 before a
secondary diagnosis of OVCA at 57 (Figure 6A). The second carrier of an ATM frameshift
mutation (OCL56) was diagnosed at 73 and had a family history of OVCA (two additional cases
besides herself) as well as two cases of breast cancer, all on the maternal side (Figure 6B).
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A. Kindred OCF28-1

B. Kindred OCL56

Figure 6. ATM LOF variants may lead to increased OVCA risk A. Kindred OCF28-1.
Proband (indicated with arrow) is positive for ATM c.2503_2507del pathogenic variant. B.
Kindred OCL56. Proband (indicated with arrow) is positive for ATM c.5697_5698insA
pathogenic variant.
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The second gene featuring pathogenic variants in our sample, RAD51D (paralog of
RAD51), has recently been identified as a moderately penetrant gene in hereditary ovarian cancer
(Janatova et al., 2015; Thompson et al., 2013; Meindl et al., 2010). RAD51D forms a complex
with RAD51B, RAD51C and XRCC2 in order to bind single stranded DNA, a necessary process
for DNA repair by homologous recombination and is required for RAD51 foci formation upon
DNA damage induction (Tarsounas, Davies, and West, 2004). Although rare among familial
breast cancer patients (Thompson et al., 2013), loss of function variants in RAD51D have been
associated with a relative risk for OVCA of 6.30. (95% CI 2.86-13.85) (Loveday et al., 2016).
Two pathogenic nonsense SNPs in RAD51D were discovered in our sample.

One carrier

(OCH26) was diagnosed at the age of 61 and had a family history of prostate (n=2), breast (n=2)
and ovarian cancer on her paternal side, while the second carrier (OCK1), diagnosed at 67, had a
comparatively weak family history with a single diagnosis of colon cancer on her paternal side
and lung cancer in a maternal aunt.
In addition, a pathogenic nonsense mutation in a non-panel gene, FANCM (rs144567652,
p.R1931*) was identified. This variant has been recently associated with increased risk of breast
cancer (OR of 3.93) (Peterlongo et al., 2015), warranting contact for further counseling.
FANCM is the most highly conserved member of the Fanconi Anemia Complementation Group
(Schwab et al., 2015). This group is associated with the autosomal recessive genetic disorder,
Fanconi Anemia, which is characterized by genomic instability, hypersensitivity to DNA damage
induced by crosslinking agents and substantial increased risk of leukemia and other cancers
(Bogliolo and Surrallés, 2015). Other members of the Fanconi Anemia complementation group
include breast and ovarian cancer-associated genes; RAD51C (FANCO), BRCA1 (FANCS),
BRCA2 (FANCD1), BRIP1 (FANCJ) and PALB2 (FANCN). FANCM encodes for an ATP-
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dependent helicase important for the resolution of DNA: RNA hybrids, thus ensuring stability
with genome duplication (Schwab et al., 2015). The nonsense variant identified here has been
shown to affect protein function by also inducing exon skipping (Peterlongo et al., 2015). The
carrier (OCJ19) of FANCM rs144567652 was diagnosed with OVCA at 49 years of age and had
a family history of breast (n=2), multiple myeloma, leukemia, and ovarian, all on the maternal
side of her family (Figure 7).

52

Kindred OCJ19

Figure 7. Kindred OCJ19. Proband is carrier of FANCM pathogenic variant
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3.2 Variants of unknown clinical significance detected in HBOC panel genes
As most women in our sample were not found to be carriers of a clearly pathogenic
mutation upon WES, I next sought to identify potentially deleterious variants in HBOC panel
genes and found that 23 women in the sample (37%) harbored one or more rare and predicted to
be damaging variants of unknown significance (VUS), in panel genes; ATM, BRCA1, BRCA2,
CHK2, MHS6, MUTHY, NBN, PALB2, and PMS2 (Table 7). Analysis of the Human Gene
Mutation Database (HGMD) (Stenson et al., 2003) revealed that six of these variants are
annotated as “disease causing” (DM), ten as “possibly disease causing” (DM?) and three as
“disease associated polymorphism” (DP) in the Human Gene Mutation Database (HGMD)
(Stenson et al., 2003).
Carriers of deleterious variants in either ATM, CHK2, PALB2 or NBN are typically
counseled for their risk of breast cancer, but not ovarian cancer despite associations in current
literature (Walsh et al., 2011; Thorstenson et al., 2003; Norquist et al., 2015; Lawrenson et al.,
2015)..

In addition to the pathogenic ATM frameshift mutations previously discussed, we

detected an additional six rare and predicted to be damaging missense VUSs in ATM; rs1800054,
rs138327406, rs28904919, rs1801673, rs56009889, rs35203200. The ATM variant rs1800054
(p.S49C) has recently been implicated as associated with a slightly increased risk for breast
cancer (OR 1.08 (C.I .95-1.22) for heterozygotes, 1.44 (.39-5.32) for homozygotes (Fletcher et
al., 2010). ATM variant rs138327406 (p.F1463C MAF= 0.002) is listed as a disease-causing
mutation in HGMD and was found in three of six women of Ashkenazi Jewish (AJ) descent in
our sample, always in combination with a second rare polymorphism 266 amino acids apart
(rs2227922, p.P604S, MAF=0.003) which was predicted to be benign. These variants were not
seen in any other women in our sample and linkage data suggests they are not in disequilibrium
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(r2 =0.5, Haploreg v4, CEU). Therefore, it is suspected that there may be a founder effect
resulting in the coupled segregation on a single haploblock in the AJ population. One participant
(OCG29) was found to have inherited both variants on the same parental allele. We were not
able to confirm co-segregation in the other two participants as fresh peripheral blood samples
were not available to prepare RNA for this analysis. However, we did find that the unaffected
daughter of OCD16 was wild type for both variants, suggesting likely co-segregation.
Similarly, with PALB2, a detected a pair of rare SNPs inherited together, rs45532440
(p.E672Q MAF= 0.02) and rs45551636 (p.G998E MAF= 0.02) r2=0.69, in two unrelated
individuals (OCH26 and OCE17-2). PALB2 (partner and localizer of BRCA2), physically
interacts with BRCA2, and is critical for the localization and stability of BRCA2 in the nucleus.
Females with monoallelic germline loss of PALB2 have a 2-4 fold increased breast cancer risk
(Rahman et al., 2010; Erkko et al., 2007). CHK2 and NBN are also known breast cancerassociated genes in which we found an interesting VUS in our sample. Female CHK2 and NBN
pathogenic mutation carriers are at an increased lifetime risk of developing breast cancer with a
2-fold for CHK2 and 3-fold for NBN carriers, (The CHEK2 Breast Cancer Case-Control
Consortium 2004). Both patients had a family history of breast cancer and the carrier of CHK2
had a secondary diagnosis of breast cancer. The p.I232V (rs587780185) variant in CHK2 is
extremely rare (MAF= 00001). SIFT and PolyPhen predict this alteration as deleterious and
probably damaging. NBN p.I171V (rs61754966) has contradictory annotations among various
bioinformatics assessment tools, but is annotated as a disease-causing mutation in HGMD.
Numerous potentially deleterious VUSs in Lynch syndrome and familial adenomatous
polyposis associated genes were detected in the study sample. Lynch syndrome (hereditary
nonpolyposis colorectal cancer), is an autosomal dominant inherited disorder caused by
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mutations in mismatch repair genes; MLH1, MSH2, MSH6, PMS2, or EPCAM which lead to high
risk of colorectal cancer (80% lifetime risk) among others, including cancer of the ovaries (1015% lifetime risk) and endometrium (71% lifetime risk) (Strafford, 2012). Skin cancer, in the
form of Muir-Torre syndrome (a variant of Lynch) is another non-colonic phenotype observed in
some Lynch families (Bansidhar, 2012; South et al., 2008).

A rare (MAF=0.007), highly

conserved (GERP=5.35) and predicted as deleterious VUS was found in the Lynch associated
gene, MHS6 (p.V509A rs63751005). The carrier of this SNP (OCD16) was diagnosed with
OVCA at the age of 25, followed by a secondary diagnosis of colon cancer at the age of 65 and
had a family history of colon and skin cancer as well. Two patients in the sample were
heterozygous for very rare missense MUTHY mutations considered to be pathogenic and the
cause of MYH-associated polyposis (MAP) in homozygote carriers (rs34612342 p.Y179C
MAF= 0.002 and rs36053993 p.G396D MAF= 0.003). Although it is possible that a second
pathogenic MUTHY variant occurred sporadically in the other parental allele, tissue was
unavailable to detect this change in these patients. Biallelic mutations in MUTYH have been
shown to mimic Lynch syndrome by disrupting base excision repair and resulting in a somatic
loss of function of mismatch repair (Morak et al., 2014). The carrier of the MUTYH variant,
rs34612342, (OCE17-2) had a family history of skin and breast cancer and was a carrier of an
additional VUS in the Lynch gene PMS2. The carrier of MUTHY rs36053993 (OCQ15) was also
diagnosed with melanoma and had a family history of colon (n=2) skin (n=2) and ovarian cancer.
Another conspicuous finding in our sample was the occurrence of a specific BRCA2
truncating mutation in four unrelated individuals. The BRCA2 variant p.K3326* (rs11571833)
results in a 93-amino acid truncation and has a minor allele frequency (MAF) of 0.009 (EXAC
non-Finnish). The odds ratio of observing this mutation in our sample relative to its MAF in the
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ExAC cohort is 4.95 (Fisher’s Exact test p-value = 0.01). It is worth noting that this allele is
much more frequent in the Finnish population (MAF=.01). However, even using this more
frequent MAF as a reference, our test indicates that the allele is still significantly overrepresented
(p = 0.03, OR = 3.71). Although the role of BRCA2 has been established in breast and ovarian
cancer, the K3326* variant is considered to be benign by commercial testing and therefore was
not identified in the initial BRCA1/BRCA2 screening.

However, recent literature is in

disagreement with this classification and established that this SNP is a risk factor for lung, oral
and pancreatic cancers (Akbari et al., 2008; Martin et al., 2005; Rudd et al., 2006) all of which
were observed in the family histories of the four K3326* carriers; throat (OCP36), lung (OCK1
and OCF28-1) pancreatic (OCN22), and esophageal cancer (OCN22). The accepted risk for
breast cancer in carriers of this SNP is low but significant (p = 0.047, OR 1.53, 95% CI 1.002.34) (Thompson et al. 2015). Two of the four carriers had a family history of breast cancer, one
of which had a primary diagnosis of breast cancer prior to ovarian cancer. Furthermore, analysis
of the GAME-ON database (>15000 OVCA cases and >30,000 controls) indicates that this SNP
is also associated with OVCA with a p-value of 2.7x10-4 and OR (95% CI) = 1.31 (1.22-9.32) for
all histologies, and for 8,864 invasive serous OVCA cases versus controls, the p-value was
7.11x10-8 and OR (95% CI) = 1.57 (1.44-1.70). This data was provided by the Ovarian Cancer
Association Consortium (OCAC) (http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/). These
findings indicate that BRCA2 K3326* is likely a low risk allele in ovarian cancer.
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Table 7. Rare and predicted to be deleterious/damaging variants of unknown clinical
significance in sample. AA= Amino acid change, MAF= Minor allele frequency (ExAC,
European non-Finnish) OBS= Number of times variant was observed in sample. MUT PRED=
Mutation predictor risk assessment, LRT= Likely hood Ratio Test for functional predicting of
mutation, DEL= deleterious, TOL= Tolerated NEUT= Neutral, MUT TAST= Mutation Taster
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prediction, DC= Probably Disease Causing, PM= Probably Polymorphism, GERP= Genomic
Evolutionary Rate Profiling, a score above 2 indicates a highly constrained sequence, HGMD
Variant class; DM= Disease causing mutation, DM?= Possible disease causing mutation, DP=
Disease associated mutation, N/A= Not Available. All variants listed were confirmed by Sanger
DNA Sequencing.
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3.3 High impact mutations in non-panel candidate genes
A portion of the missing heritability in OVCA is likely due to risk factors in genes not
currently featured on testing panels. The implication of even a highly penetrant mutation would
be difficult to interpret if rare, even in a mechanistically relevant gene not previously associated
with the disease. Despite selecting for patients with high risk of genetic inheritance, half of the
subjects in our sample were not found to harbor a pathogenic variant, nor a variant of unknown
significance in any of the 24 panel genes currently tested in HBOC syndromes (Figure 8). I
therefore sought to identify rare (MAF ≤ 0.02) mutations in our sample of high functional impact
(frameshift or stop gain) in candidate genes.

Using DAVID (https://david.ncifcrf.gov/)

functional annotation and literary searches I compiled a candidate gene list including 115 genes
involved in DNA repair and/or cell cycle control, the two pathways most commonly associated
with HBOC, in addition to 64 genes having a disease-causing variant (DM) in HGMD for
ovarian cancer. A full list of non- panel candidate genes analyzed is provided in methodology
section (Table 4).
This analysis uncovered 11 high impact mutations in four cell cycle control genes,
CHK1, RAD1, TP53I3 (n=2), MCM4, and six DNA repair genes, FANCM, HMMR, POLK,
POLQ, RAD52 (n=2), and REC8 (Table 8). Importantly, this analysis resulted in the discovery
of a clinically actionable pathogenic nonsense variant in FANCM (rs144567652) previously
discussed. Most of these non-panel genes are not featured in HGMD, and are they are not
analyzed during clinical testing. Therefore, I have provided the mouse phenotype seen in knockout studies where possible.

A common phenotypic presentation of many known cancer

predisposition genes, such as BRCA1/2, includes embryonic lethality in homozygote knockouts
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and increased cancer incidence in heterozygotes, which are reported in mouse model studies of
some of these genes (Table 8).
The frameshift mutation in CHK1 (Checkpoint Kinase 1) is notable because much like
panel gene CHK2, it encodes for a serine/threonine protein kinase required for checkpointmediated cell cycle arrest and activation of DNA repair HRR. I also discovered a frameshift
variant in RAD1, a gene whose protein product functions as part of the 9-1-1 cell cycle
checkpoint complex to arrest cellular proliferation in the presence of incomplete DNA
replication or damaged DNA, as well as in MCM4 (Mini-chromosome maintenance complex
component 4), a highly conserved helicase protein required for genome replication by initiation
of replication fork formation (Sheu et al., 2014).

The TP53I3 (TP53 inducible protein 3)

nonsense SNP (rs145078765 p. S252* MAF= 0.0009) is also of great interest as it was observed
in two unrelated individuals in our sample. TP53I3 is an oxidoreductase-like protein and an
inducer of reactive oxygen species (ROS), that is transcriptionally activated by the tumor
suppressor P53 and likely to be involved in P53-mediated apoptosis (Zhang et al., 2015).
Among DNA repair genes, I observed high impact mutations in those encoding DNA
polymerases, POLK (c.1336del), a translesion polymerase that initiates the continuation of
replication through DNA lesions in damaged DNA, and POLQ (p.Q2513* rs148626322), a gene
associated with micro homology-mediated end-joining pathway (MMEJ), both in the same
patient. I also identified truncating variants in chromatid cohesion REC8, whose protein product
binds sister chromatids during meiosis, and HMMR (hyaluronan mediated mobility receptor),
which encodes for a cell motility protein that forms a complex with tumor suppressors BRCA1
and BRCA2. Common missense variations in HMMR have been shown to modify the penetrance
of breast cancer risk in BRCA1 pathogenic mutation carriers (Maxwell et al., 2011).
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Furthermore, two RAD52 truncating SNPs; rs4987207 p.S346* and rs4987208 p.Y415* were
discovered.

RAD52 mediates complementary ssDNA annealing and recruits RAD51

recombinase to promote recombination and HRR. However, the RAD52 truncating variants
observed in our sample had previously been found to lack an association with OVCA or breast
cancer (J. Han et al., 2002).
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Figure 8. Summary of variant findings amongst our 48 subjects of high risk for
genetic inheritance of OVCA.
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Table 8. High Impact Mutations in DNA repair and Cell Cycle Control Genes, not
Featured on HBOC Testing Panels. Rare and high impact variants (frameshift or stop gain) in
sample found in DNA repair or cell cycle control genes not currently known to associate with
breast or ovarian cancer. MAF=Minor Allele Frequency in Non-Finish Europeans (ExAC).
Mouse Phenotype= Available phenotypic information on homozygote (-/-) or heterozygote (+/-)
mouse knock out models. Ovary expression data RPKM (reads per kilobase per million) obtained
by https://gtexportal.org. *For reference, OVCA genes BRCA1=.6, BRCA2= .095, RAD51D= 4.
All variants listed were confirmed by Sanger DNA Sequencing.
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3.4 BRCA2 p.K3326* truncation as a possible modifier of penetrance
The prevalence of the BRCA2 K3326* variant (Figure 9A) in our sample, along with the
evidence of an association with lung, aero digestive, and pancreatic cancer (Akbari et al. 2008;
Martin et al. 2005; Rudd et al. 2006) indicate that this variant may be of minimal risk when
inherited alone but could act as a modifier of penetrance to a secondary more deleterious
mutation. A portion of the missing heritability in OVCA is likely due to this type of polygenic
inheritance. This possibility led to the investigation of other putative pathogenic variants that
each of the four carriers had inherited in addition to BRCA2 p.K3326* (Table 4). I therefore
looked for additional rare, and moderate or high impact variants in either HBOC panel genes or
candidate genes (involved in DNA repair/cell cycle and with cancer associations in HGMD)
amongst the four BRCA2 K3326* carriers. A complete list of rare and predicted to be damaging
variants of moderate impact in cell cycle and DNA repair genes is available in the appendix
(Table 12).
In analyzing relevant candidate genes, I identified two patients who along with K3326*
were carriers of an additional, clearly pathogenic variant; a RAD51D nonsense mutation (OCK1)
and ATM frameshift mutation (OCF28-1). This observation is interesting because BRCA2
interacts with the RAD51 paralogs and a BRCA2/RAD51D double knockdown leads to a greater
loss of cellular viability (Jensen et al., 2013). The carrier of both the ATM frameshift and
BRCA2 K3326* variants developed both breast and ovarian cancer. Sequencing of some of her
immediate family members at these loci determined that both variants were inherited from her
father, who died of liver cancer and a twin sibling and paternal grandfather of the patient, both of
whom died of lung cancer (a disease associated with this SNP), but whose genotypes are not
available (Yufei Wang et al., 2015). A second female sibling of this patient had inherited the
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ATM frameshift but not the BRCA2 K3326* variant and developed breast cancer at the age of 46
(Figure 9B).
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A.

B.

Figure 9. BRCA2 K3326* may be a modifier of penetrance A. BRCA2 protein schematic
depicting site of truncation p.K3326* variant. Variant occurs at the C-Terminus (red) which
occurs in a RAD51 binding domain and site of CDK2 phosphorylation. B. OCF28 kindred. Arrow
indicates patient OCF28-1 Kindred of proband (arrow) with p.K3326* plus pathogenic ATM

frameshift shows inheritance of both alleles from an affected father.
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Carriers of BRCA2 p.K3326* and additional variants of interest
Patient
ID
OCF28-1

OCK1

OCN22

OCP36

Gene

Consequence

Amino Acids

dbSNP ID

Variant

MAF

HGMD cancer

SIFT

PolyPhen

phenotype

ATM

FRAMESHIFT

N/A

c.2503_2507del

N/A

Breast/Ovarian

N/A

N/A

STOP

CATCTG>C
Exon 13
K3326*

BRCA2

rs11571833

c.9976A>T

0.009

Breast/Ovarian

N/A

N/A

PALLD

MISSENSE

R303S

rs138897963

c.909A>T

0.001

Pancreatic

TOL

Probably
Damaging

ATM

MISSENSE

F1463C

rs138327406

c.4388T>G

0.002

Breast/Ovarian

DEL

BRCA2

STOP

K3326*

rs11571833

c.9976A>T

0.009

Breast/Ovarian

N/A

Probably
Damaging
N/A

ERCC6

MISSENSE

M713V

rs201486862

c.2137A>G

0.00001

DEL

Benign

HMMR

STOP

E352*

rs146791423

c.1054G>T

0.003

Basal cell carcinoma,
Cockayne syndrome,
None

N/A

N/A

RAD51D

STOP

R206*

rs387906843

c.616C>T

0.00001

Breast/Ovarian

N/A

N/A

RECQL

MISSENSE

C321Y

rs150889040

c.962G>A

0.00001

Breast

N/A

Probably
Damaging

BRCA2

STOP

K3326*

rs11571833

c.9976A>T

0.009

Breast/Ovarian

N/A

N/A

BUB1B

MISSENSE

E409D

rs28989188

c.1227A>C

0.0004

Gastrointestinal

TOL

Probably
Damaging

BRCA2

STOP

K3326*

rs11571833

c.9976A>T

0.009

Breast/Ovarian

N/A

N/A

AXIN1

MISSENSE

V340M

rs143974067

c.1018G>A

0.00004

Colorectal adenoma

DEL

Probably
Damaging

Table 9. Additional VUSs in carriers of BRCA2 K3326* Rare and predicted to be
deleterious/damaging variants (SIFT/PolyPhen-2) found in carriers of BRCA2 p.K3326*. MAF=
Minor allele frequency (ExAC, European non-Finnish) OBS= Number of times variant was
observed in sample, DEL= deleterious TOL= Tolerated, N/A= Not Available. All variants listed
were confirmed by Sanger DNA Sequencing.
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CHAPTER 4: DISCUSSION PART I
We performed WES on 48 women with OVCA and suspected to have an inherited cancer
predisposition, yet, were previously tested and found negative for known pathogenic mutations
in either BRCA1 or BRCA2. In doing so, we discovered pathogenic variants in ATM (n=2) and
FANCM (n=1), genes currently associated with breast cancer but not OVCA, as well as in a gene
recently implicated in hereditary ovarian cancer risk, RAD51D (n=2). These findings suggest
that carriers of ATM and FANCM pathogenic mutations are possibly at elevated risk of
developing OVCA as well as breast cancer and that the underling genetics of these two cancers
may overlap more than previously believed. Available expression data via GTEx Portal (Broad
Institute) indicate both genes have higher RPKM (reads per kilobase per million) scores in ovary
tissue versus breast; ATM =3.6 breast, 8.7 ovary and FANCM =.89 breast, 1.1 ovary
(https://gtexportal.org) indicating that these genes are expressed in ovarian cells. Furthermore,
the results from WES indicate that there is clinical value of resequencing BRCA1/2 negative
individuals that fit current NCCN guidelines and whose genetic risk was assessed before the era
of multi-gene panel testing.

4.1 WES highlights three likely sources of missing heritability
The majority of the high risk OVCA participants in our WES sample set did not harbor a
known clinically actionable cancer predisposing mutation upon reanalysis with whole exome
sequencing even in known panel genes, emphasizing the current challenge for genetic testing and
counseling in clinical cancer care. Despite the large heritable component to OVCA, the majority
of underlying genetic risk remains unexplained (Pharoah et al., 2013). Although many novel
putative risk loci were discovered, most are rare or private familial missense mutations of
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unknown clinical significance and not found in the published literature. The rarity of these
variants also means that they would not be identifiable in GWAS studies.
4.1.1 Variants of Unknown Significance
Many high-risk women who undergo testing for HBOC are found to be carriers of one or
more “variants of unknown significance” (VUSs), (Domchek and Weber, 2008) a rare, generally
missense mutations, unannotated in their consequence to disease risk rather than a clearly
pathogenic variant.

Although the functional consequence of high impact variants such as

nonsense and frameshift mutations are straightforward to interpret, missense mutations which
result in single amino acid substitutions are of ambiguous significance. I observed suspicious
missense VUSs in HBOC panel genes employing well-accepted bioinformatics techniques:
BRCA1, BRCA2, CHK2, MUTHY, MHS6, NBN, PMS2, and most notably in ATM and PALB2.
Overall, such suspicious variants in 23 of our 48 test subjects were uncovered.
The ability to assess VUSs is crucial to closing the gap in unexplained heritability while
aiding in more informed clinical decisions. A common approach to implicating a VUS is by
linkage analysis, whereby the causal mutation is expected to segregate with the disease in one or
more families.

Unfortunately, DNA samples from other affected and non-affected family

members are generally not often available. A linkage analysis is also not ideal for low to
moderate risk factors because these variants are not highly penetrant. Bioinformatic prediction
tools for variant consequence on protein function, such as SIFT and PolyPhen, are very useful
for prioritizing variants for follow up. However, in silico assessment tools such as these often
contradict each other and are not considered to have enough sensitivity and specificity to inform
clinical decisions (Richards et al., 2015). Despite the advent of detailed guidelines for variant
interpretation, many variants in ClinVar list numerous testing facility submissions with
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conflicting interpretations of pathogenicity.

Thus, the vast majority of single nucleotide

polymorphisms (SNPs) in cancer-relevant genes remain unannotated as to whether the change is
deleterious to protein function and potentially disease causing.
4.1.2 Polygenic risk loci
Further complicating this issue is that under a polygenic model for hereditary cancer risk,
carriers of multiple low penetrant genetic variants could be at high risk (Johnson et al., 2007),
meaning much of the unexplained heritability in OVCA may be due to more than one genetic
risk factor that, when inherited together, have an additive or synergistic effect. One variant in
BRCA2 (p.K3326*) stood out as a possible modifier of penetrance due to an almost five-fold
increased occurrence over expected and the observation that two of the four women carrying this
SNP also had a pathogenic mutation of moderate effect in a second low penetrance gene
involved in DNA repair, (ATM and RAD51D). This SNP results in a 93-amino acid truncation
and is reported as benign according to genetic testing services, mostly due to weak disease cosegregation in familial studies. This assessment has been questioned in recent literature due to
its association with other cancers. Functional data have suggested that K3326* acts similar to
wild type BRCA2 for recombination repair and MMC sensitivity (K. Wu et al., 2005). However,
the K3326* truncation is located at the C-terminus of the BRCA2 protein (exon 27), and deletion
of this domain has been shown to result in reduced cellular response to stalled and collapsed
replication forks, (T. M. Kim et al. 2014) hypersensitivity to gamma-radiation and premature
senescence (Morimatsu, Donoho, and Hasty, 1998). Additional evidence in the literature along
with our findings suggest the possibility that this variant that may be of minimal effect alone but
enhances the penetrance of another moderately penetrant inherited variant in the same functional
pathway. This would explain the weak genotype to phenotype correlation with this variant as

71
well as the observation that this variant has been found in-trans with other pathogenic BRCA2
mutations, without causing Fanconi Anemia. Due to our small sample set, the occurrence of this
SNP with additional moderate pathogenic mutations in the same pathway could be by chance.
However, in agreement with the hypothesis of a role as a possible modifier of penetrance, the
BRCA2 K3326* truncation is found in The Cancer Genome Atlas (TCGA) database three times,
each in OVCA patients who are all also carriers of pathogenic genetic variants; (TCGA-24-156201 with an NF1 frameshift, aTCGA-13-1512-01 and TCGA-23-1026-01 with BRCA1 frameshift
mutations (http://cancergenome.nih.gov).
4.1.3 Novel genes yet to be implicated in risk association studies
It is likely additional risk genes exist that, when mutated, predispose to breast and/or
ovarian cancer, but have yet to be implicated due to their rarity or low penetrance. In my attempt
to discover novel OVCA predisposition genes, I chose to focus on genes involved in DNA repair
or cell cycle control as these two dynamic and interrelated pathways are crucial to genomic
stability and are the most mutated pathways in hereditary breast and ovarian cancers. In doing
so, I discovered 11 high impact mutations in genes that are not featured on current HBOC risk
assessment panels (CHK1, FANCM, HMMR, MCM4, POLK, POLQ, RAD1, RAD52, REC8, and
TP53I3) but have very similar or overlapping functions to those genes on commercial panels.
The finding of a pathogenic variant in FANCM during this specific analysis is promising as it
affirms the candidate gene rationale and marks the first known case of a FANCM deleterious
variant in an ovarian cancer patient. Of the eleven variants discovered in this analysis, five were
novel. The rarity of these high impact variants is likely due to the essential natures of the DNA
repair and cell cycle pathways. Knock out mouse model studies of CHK1, MCM4, and RAD1 all
show embryonic lethality in homozygous null mice and increased cancer incidence in
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heterozygotes (Table 8), similarly to BRCA1/2, which makes them compelling and worthy of
following up with functional studies. This study is the first of its kind to describe these germline
loss of function variants in ovarian cancer patients with inherited risk. Further work should
include analyzing genes in other cancer related pathways since risk loci may also occur in
mechanisms not involved in DNA repair or cell cycle control.

4.2 Functional assessment is necessary to implicate novel genetic loci identified by
bioinformatics tools
One key challenge facing genetic testing and counseling in clinical cancer care is the
functional significance of VUSs in cancer-associated genes as well as loss of function variants in
candidate risk genes. This information is necessary to provide genetics professionals with
guidance for better informed patient risk evaluation, risk reduction strategies and possibly
improved therapeutic modalities.

While bioinformatics tools for assessment are useful for

variant filtering purposes, they are not sensitive enough for clinical decisions. Ideally, missense
variants predicted by bioinformatics algorithms to be ‘pathogenic’ or ‘likely pathogenic’ and
novel candidate genes found with high impact mutations would be functionally tested using
sensitive and specific assays that add to computational evidence for clinical insights. Because a
single low-to-moderately deleterious mutation may appear inconsequential alone but could
modify the penetrance of a deleterious mutation in the same pathway, combining the risk of
multiple genetic variants may also lead to better risk assessment.
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CHAPTER 5: RESULTS PART II
Analysis of WES data from 48 high risk women with OVCA revealed 11 loss of function
variants in genes not already implicated in hereditary OVCA risk, but whose protein products are
involved in DNA repair and/or cell cycle control, the two most commonly mutated pathways in
HBOC. Because hereditary OVCA is rare, displays variable penetrance, and has a high degree
of underlying genetic heterogeneity, the implication of a novel gene, especially of high
penetrance, is unlikely to occur through case control associative studies. Therefore, I chose to
functionally assess various candidate genes found mutated in our cohort. Specifically, FANCM,
CHK1, MCM4, RAD1, and REC8 were of interest due to their conservation and cancerassociated mouse model phenotype which includes embryonic lethality in homozygote
knockouts and increased cancer incidence in heterozygotes. I was particularly interested in
TP53I3 because a very rare high impact mutation in this gene occurred twice in our cohort in
unrelated individuals.

Also there was very limited functional data and no mouse model

phenotype in the literature. Finally, HMMR was also chosen because it has been shown to form
a complex with BRCA1/BRCA2 and common missense variations in this gene have been shown
to modify the penetrance of breast cancer risk in BRCA1 pathogenic mutation carriers (Maxwell
et al., 2011).
Genes chosen as positive controls for functional analyses include HBOC risk genes
BRCA1 and BRCA2 (high risk) as well as ATM, CHK1, RAD51D (moderate risk). The choice of
multiple positive controls with both high and moderate penetrance was to gauge the sensitivity of
the assays employed for both highly and moderately penetrant genes as well as to determine
whether they could distinguish between a gene of high penetrance and one of moderate
penetrance. Two highly sensitive assays were employed to measure involvement in homologous
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recombination repair (HRR) and sensitivity to DNA damage induction; the HRR Assay and
clonogenic survival assay, respectively (see Materials and Methods sections 2.8 and 2.9). The
HRR assay quantifies the efficiency of the cell’s endogenous HRR pathway by inducing double
strand DNA breaks (DSB) into cells with a non-functional and stably transfected GFP allele.
The GFP allele will only become active once the DSB repair has occurred, therefore the amount
of GFP induction proxies for the efficiency of the HRR pathway. This method accurately assays
a gene’s involvement in the HRR pathway by measuring the amount of GFP observed after
siRNA knock down as compared to a scramble siRNA control after DSB induction.

The

clonogenic survival assay is a commonly applied tool to assay a gene’s involvement in cell
survival as well as to measure drug cytotoxicity. It is often used to determine the effectiveness
of chemotherapeutic reagents under various tumor genetic profiles. All functional analyses were
carried out with the use of small inhibitory RNAs (siRNA), which interfere with the expression
of a targeted gene by preventing mRNA translation. Knock downs achieved by siRNA were
verified by western blotting technique described in Materials and Methods section 2.7 “Protein
Detection and Quantification.” These blots are featured in the appendix of this manuscript.

5.1 Knock down of various candidate genes found mutated in cohort lead to reduced
homologous recombination repair efficiency
Using the HRR protocol described in section 2.8, I compared the amount of GFP
observed 48 hours after I-SCEI DSB induction among cells with siRNA knockdown of both
candidate and control genes to cells with no knock down (scramble siRNA control).

All

conditions were adjusted for a negative control background (empty plasmid in place of I-SCEI
plus scramble siRNA). Five to six replicates represent each condition to reduce inflation of Type
II error. siRNA knock down of panel genes tested (BRCA1, BRCA2, ATM, CHK2 and RAD51D),
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led to a significant decrease in HRR efficiency after siRNA knock down. Notably, knock down
of BRCA1 and BRCA2 led to the highest reduction in HRR efficiency (approximately 70% and
89% less compared to scramble control respectively (reported as mean difference MD)) while
ATM, CHK2 and RAD51D knock down led to moderate reduction in HRR efficiency (45% 27%,
and 35% reduction respectively), consistent with their roles as moderately penetrant genes.
siRNA depletion of candidate genes REC8, TP53I3, CHK1 and FANCM all lead to a significant
reduction in HRR. The greatest reduction amongst candidate genes was observed with CHK1
which was similar to BRCA1 and lead to a reduction of 69.2% (p=<0.001). The next largest
reduction in HRR efficiency was observed with FANCM, (MD= 54.1, p=<0.001). Knock down
of TP53I3 led to a reduction of 33% (p=0.001) and REC8 with a modest reduction of 14.8%
(p=0.001). siRNA depletion of RAD1 did not lead to a decrease in HRR efficiency but seemed
to trend towards an increase. While this is not statistically significant, biologically it would make
sense since RAD1 is believed to play a role in microhomology-mediated end joining (MMEJ) for
the repair of ionizing radiation and chemicals that induce DSBs (Ma et al., 2003). Therefore,
cells depleted of RAD1 may be more reliant on the HRR pathway for DSB repair. One study has
shown RAD1 as indispensable to microhomology-mediated end joining (MMEJ) for the repair of
ionizing radiation and chemicals that induce DSBs (Ma et al. 2003).

Non-Panel

Panel
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Gene
Scramble
ATM
BRCA1
BRCA2
CHK2
RAD51D
FANCM
CHEK1
RAD1
REC8
TP53I3

M
97.4
51.9
27.5
8.6
70.3
62.8
43.3
28.2
108.7
82.6
64.4

SD
2.58
13.43
8.32
5.02
9.96
12.61
6.68
14.04
7.57
5.68
13.55

MD
---45.5
-69.9
-88.8
-27.1
-34.7
-54.1
-69.2
11.2
-14.8
-33.0

t
--6.72
21.45
39.97
5.98
5.452
21.53
11.95
-2.52
6.40
7.55

p
--0.006
0.000
0.000
0.003
0.011
0.000
0.000
0.119
0.000
0.000

Figure 10. HRR efficiency after siRNA knockdown. M = Mean % of GFP; SD = Standard
deviation; MD = mean difference as compared to scramble control. t = statistical test for mean
difference; * p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant. Data normalized
to negative control for GFP background signal and positive control for GFP induction.

77

5.2 Knock down of RAD1, CHK1 or FANCM lead to a decrease in cellular viability
One key genetic mechanism in the process of tumorigenesis is the loss of heterozygosity
(LOH) at tumor suppressor loci leading to the “inactivation” of genes required for the regulation
of cell growth and differentiation (Ryland et al., 2015). Functional loss of genes essential for
cellular viability is known to encourage LOH (Yuxun Wang et al., 2010) and is associated with
increased cancer risk. For instance, ovarian breast cancer risk genes BRCA1 or BRCA2 are both
involved in cellular viability. To identify which of the candidate genes are also involved with
cellular viability, I compared the clonogenic survival of cells after siRNA knockdown of
candidate and control genes to a scramble siRNA control (Figure 11). Five to six replicates
represent each condition repeated to reduce inflation of Type II error. Among panel genes
tested, siRNA knock down of either ATM, BRCA1 or BRCA2 lead to significant a loss of
clonogenic survival. There was no loss of cellular viability observed for panel genes CHK2 or
RAD51D. For candidate gene CHK1, there was a loss of clonogenic survival similar to BRCA1
and BRCA2 (CHK1 = mean survival of 13.8%, BRCA1 = mean survival of 16.5%, BRCA2 =
mean survival of 8.8%). In addition, siRNA knock down of candidate gene RAD1 led to a
reduction in clonogenic survival that was similar to that observed with ATM (mean survival of
23.3% vs 29.6% respectively). Most interestingly, siRNA depletion of FANCM led to the
greatest loss in clonogenic survival with a mean plating efficiency of just 2%.

Non-Panel

Panel
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Gene
Scramble
ATM
BRCA1
BRCA2
CHK2
RAD51D
FANCM
CHK1
HMMR
MCM4
RAD1
REC8
TP53I3

M
42.4
29.6
16.5
8.8
35.7
37.7
2.1
13.8
43.8
40.0
23.3
42.6
37.8

SD
5.44
10.06
3.54
6.59
5.54
11.94
1.83
6.37
17.09
7.87
8.82
4.78
8.98

MD
---12.8
-25.9
-33.6
-6.7
-4.7
-40.3
-28.6
1.4
-2.4
-19.1
0.2
-4.6

t
---2.55
-9.78
-9.62
-2.12
-0.88
-17.2
-8.37
0.19
-0.61
-4.51
0.06
-1.07

p
--0.044
0.000
0.000
0.060
0.406
0.000
0.000
0.855
0.554
0.002
0.952
0.315

Figure 11. Plating efficiency after siRNA knock down. M = Mean % survival; SD = Standard
deviation; MD = mean difference as compared to scramble control. t = statistical test for mean
difference; * p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant.
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5.3 Cells deficient in CHK1, RAD1, TP53I3 or REC8 display significant sensitivity
to DNA damage
Genomic stability is directly related to a cell’s DNA repair efficiency. Cells deficient in
DNA

repair

mechanisms

display

greater

sensitivity

to

DNA

damaging

reagents.

Chemotherapeutic drugs; Cisplatin, Etoposide, and Olaparib specifically exploit this
vulnerability and cells deficient in tumor suppressor genes BRCA1 or BRCA2 are especially
sensitive to these reagents. To assess whether, and to what extent, any of the candidate genes are
involved in DNA repair and genomic integrity, I compared the clonogenic survival of cells with
targeted siRNA depletion of candidate and panel genes to a scramble siRNA followed by
exposure to Cisplatin, Etoposide, or Olaparib. These three reagents where chosen due to their
different mechanisms regarding DNA damage and in relevance to current OVCA therapies. Cells
were exposed to the drugs 48 hours post siRNA knock down, when the targeted depletion is
greatest. Drug concentration and exposure were determined by optimizing for an IC50, which for
the purposes of these experiments, is the concentration required for 50% cytotoxicity in a
scramble siRNA knock down control. The IC50 treatment exposure for each reagent was as
follows: Cisplatin= 2 M for 2 hours, Etoposide= 10 M for 4 hours, and Olaparib 10 M for 4
hours. The clonogenic survival after drug exposure for each condition was adjusted to the
plating efficiency observed with the same siRNA knock-down and without drug exposure. Five
to six replicates represent each condition repeat to reduce inflation of Type II error. The
assessment of candidate gene FANCM to these reagents was not possible due to the extreme loss
of cellular viability that occurred after siRNA depletion.
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5.3.1 Cells deficient in CHK1, RAD1 or TP53I3 display increased sensitivity to Cisplatin
Cisplatin generates interstrand cross links (ICLs) which are covalent bonds between both
strands of a DNA duplex. ICLs inhibit crucial processes such as DNA replication, ultimately
leading to chromosomal instability. ICLs are repaired by HRR and thus, cells deficient in this
pathway are highly sensitive to DNA-damaging agents such as Cisplatin. As expected, all panel
genes included in this assay (BRCA1, BRCA2, ATM, CHK2, and RAD51D) were demonstrated to
be involved in HRR and ICL repair as targeted siRNA against their respective mRNA products
led to significantly increased cytotoxicity with Cisplatin exposure (Figure 12A, Table 10).
Specifically, loss of BRCA1 or BRCA2 leads to the most sensitivity, each with a mean
difference of approximately 40% increased cytotoxicity as compared to the scramble control.
This observation is consistent with their status as highly penetrant in cancer susceptibility when
mutated. Cells with knock down of candidate genes: CHK1, RAD1, or TP53I3 also displayed
significantly increased sensitivity to cisplatin exposure equal of greater to that observed in the
moderately penetrant panel genes ATM, RAD51D and CHK2 (Figure 12A, Table 10). Loss of
RAD1 led to the most sensitivity observed amongst candidate genes with a mean viability of
18.3% which is a 33% increased cytotoxicity as compared to the scramble control (p=<0.001).
Depletion of CHK1 and TP53I3 both led to a mean increase in cisplatin cytotoxicity of
approximately 27% (p=<0.001, p=<0.001 respectively.)

There was no increased cisplatin

cytotoxicity observed after knock-down of REC8, HMMR or MCM4.
5.3.2 Cells deficient in CHK1, REC8 or RAD1 display increased sensitivity Etoposide
Etoposide is a topoisomerase II (topoII) alpha inhibitor approved for clinical use as a
chemotherapeutic reagent in platinum resistant OVCA.

Topoisomerase II enzymes are

responsible for simultaneously cleaving both stands of the DNA double helix for the
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management of entangled and supercoiled DNA. These enzymes are essential for DNA
replication. Inhibition of topoII by Etoposide prevents the re-ligation of cleaved DNA and
therefore leads to DNA DSBs. Etoposide also results in single-strand DNA breaks (SSBs), since
it prevents the re-ligation of the stands independently of each other (Yang et al. 2009). BRCA1
and BRCA2 deficient cells have been described as sensitive to etoposide treatment
(Treszezamsky et al., 2007). Consistent with these reports, both BRCA1 and BRCA2 deficient
cells displayed significant sensitivity to Etoposide in this assay. Knock down of CHK2 or
RAD51D also led to increased Etoposide sensitivity (with approximately 30% and 14% increased
cytotoxicity respectively). Among non-panel candidate genes, CHK1, RAD1 and REC8 knock
down all resulted in increased cytotoxicity in response to Etoposide. CHK1 deficient cells
displayed a mean survival of 34.9% (p=0.024), RAD1 24.5% (p=<0.000) and REC8 35.4%
(p=0.018), which is an increase of approximately 14%, 24% and 13% in cytotoxicity versus the
scramble control respectively. (Figure 12B)
5.3.3 Cytotoxicity to Olaparib is specific to BRCA1 and BRCA2 deficient cells.
Olaparib is a PolyADP-ribose polymerase (PARP) inhibitor approved for clinical as an
adjunct to platinum-based therapies in patients with BRCA1 or BRCA2 deficiencies. Tumor cells
with mutant BRCA1 and/or BRCA2 have demonstrated to be up to 1000 times more sensitive to
PARP inhibitors as compared to WT cells (Farmer et al. 2005; Bryant et al. 2005). Cancer cells
deficient in HRR are more dependent on the PARP proteins which are involved in ssDNA break
repair by Base Excision Repair (BER). Inhibiting this pathway leads to synthetic lethality as the
cells loses its back up mechanism to repair DNA. In clinical trials, the use of PARP inhibitors
have shown to improve the progression-free survival when added to the treatment of women with
breast or ovarian cancer responsive to platinum, which induces DSBs (Robson et al., 2017;
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Ledermann, 2016; Evans and Matulonis, 2017). Olaparib used as a monotherapy has shown to
be effective in patients with germline BRCA1/2 mutation and advanced cancer (G. Kim et al.
2015; Kaufman et al., 2015). In this experiment, cells were treated with Olaparib in the absence
of cisplatin and increased cytotoxicity was specific to BRCA1 and BRCA2 deficient cells
(Figure 12C, Table 10). ATM, CHK2 and RAD51D panel genes have demonstrated a less
prominent role in HRR as compared to BRCA1 or BRCA2 (Figure 10). This observation may
indicate that sensitivity to Olaparib requires a heavier reliance on the BER pathway. It is also
possible that deficiency of ATM, CHK2 or RAD51D would lead to increased Olaparib sensitivity,
but only in conjunction with platinum-based therapy.
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A. Cisplatin

B. Etoposide

C. Olaparib
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Figure 12. Clonogenic survival rates after drug exposure by siRNA knock down A. Cell
Survival after exposure to Cisplatin by siRNA knockdown. All values adjusted to mean plating
efficiency after siRNA knockdown alone. B. Cell Survival after exposure to Etoposide by
siRNA knockdown. All values adjusted to mean plating efficiency after siRNA knockdown
alone. C. Cell Survival after exposure to Olaparib by siRNA knockdown. All values adjusted to
mean plating efficiency after siRNA knockdown alone. * p<0.05; ** p<0.01; ***p<0.001.
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Table 10. Statistical data for clonogenic survival rates after Cisplatin, Etoposide and
Olaparib treatment by siRNA knockdown. M = Mean % survival; SD = Standard deviation;
MD = mean difference as compared to scramble control. t = statistical test for mean difference;
* p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant.
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5.4. Estimating penetrance through a 2-dimensional model of cell viability and DNA
sensitivity
Most cancer-associated risk loci have incomplete penetrance.

The penetrance of a

pathogenic variant is determined by its associated lifetime risk with disease. Genes are often
described as having low, moderate, or high penetrance based on the lifetime risk associated with
a loss of function variant. BRCA1 is the most highly penetrant gene in hereditary breast and
ovarian cancer syndrome with an 80% lifetime risk of breast cancer and 50% risk of OVCA for
LOF variants.

Accurate estimates of genetic penetrance are necessary to inform clinical

decisions. Therefore, it would be optimal to evaluate novel risk genes in a manner that would
provide an indication of penetrance employing a functional test.
The two genes with the highest known penetrance for HBOC in the literature, BRCA1
and BRCA2, are important to both cellular viability and DNA repair. Loss of function of either
leads to a profound reduction of cellular viability, and increased sensitivity to DNA damaging
reagents as observed in the various functional assays employed in this study.

Functional

depletion of genes that are moderate in their penetrance, such as ATM, RAD51D and CHK2, lead
to more moderately increased DNA damage sensitivity as compared to BRCA1/BRCA2, and may
or may not impact cell viability in the absence of a cytotoxic reagent. Because cell viability and
DNA damage sensitivity can be observed independently of each other yet are both phenotypes of
a BRCA-like tumor suppressor gene, plotting genes using a two-dimensional graph based on
these phenotypical outcomes may lead to a separate geographical clustering of high and
moderately penetrant genes in HBOC risk. By plotting genes with known penetrance, we can
assess the potential of this method. If accurate, we can then use this scale to estimate the likely
risk/penetrance of candidate risk genes that act as a tumor suppressor in a BRCA-like manner.
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5.4.1 Plotting panel genes based on cell viability and DNA damage sensitivity after siRNA
knock down correctly differentiates between moderate and high penetrance
The three different chemotherapeutic drugs (Cisplatin, Etoposide and Olaparib) employed
for the clonogenic survival assays each work via three different mechanisms to exploit repair
deficiencies (see section 1.11 Targeted therapy in clinical cancer care). BRCA1 and BRCA2 are
the most highly penetrance HBOC associated genes and BRCA1 and BRCA2 deficient cells are
particularly sensitive to all three of these chemotherapeutic reagents. Cells deficient in tumor
suppressor genes that are BRCA-like but moderate in penetrance, such as ATM, RAD51D and
CHEK2, display significant but less or no increased cytotoxicity to each of these three reagents.
Therefore, in assessing the extent to which a gene is BRCA-like, it seems rationale to take into
consideration the sensitivity to all three of these reagents; Cisplatin, Etoposide and Olaparib
versus a single reagent alone.
To test this assumption, four plots were generated each with reduction in cell viability
observed without drug exposure on the Y axis and cytotoxicity observed after DNA damage on
the X axis. Figure 13A features a plot that includes the pooled cytotoxicity data across all three
tested reagents; Cisplatin, Etoposide and Olaparib. The subsequent plots were generated by only
accounting for cytotoxicity to each drug alone; Cisplatin; Figure 13B, Etoposide; Figure 13C,
and Olaparib; Figure 13D. Since we know the penetrance of the panel genes plotted (listed in
Figure 13), we can see that the first plot (Figure 13A) which features the pooled sensitivity data
across all three reagents is most accurate. With this plot, highly penetrant genes BRCA1 and
BRCA2 fall in top most section of both DNA damage sensitivity and reduction of cellular
viability (upper right), while the scramble control falls in the lowest section of both conditions
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(lower left). Panel genes ATM, RAD51D and CHK2, known to be of moderate penetrance, fall in
the middle of the graphical representation.
The statistical data generated from pooling all conditions (cell viability after knockdown
alone, and cytotoxicity to Cisplatin, Etoposide and Olaparib after siRNA knock down) is
represented in Table 11. The overall survival of cells with siRNA scramble control was 49.6%,
which is expected due to the IC50 optimization of drugs and normal plating efficiency of HeLa
cells. The survival of BRCA1 deficient cells across all conditions was 22% (p=<0.00) and
BRCA2 was 15% (p=<0.00). All moderately penetrant genes fell in a range of 30-39% survival
across all conditions and were all statistically significant. The statistical data and geographical
clustering based on these data observed across panel genes tested are concordant with the current
penetrance estimates in the literature, and with what clinicians refer to for genetic counseling and
risk management.

Therefore, this methodology could potentially be useful in estimating

candidate gene penetrance.
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A

B
HIGH

HIGH

MODERATE

MODERATE

CONTROL

CONTROL

Cytotoxicity to Etoposide (%)

Cytotoxicity to DNA damage (%)

C

D

HIGH

HIGH

MODERATE

MODERATE

CONTROL

CONTROL

Cytotoxicity to Cisplatin (%)

Breast

Cytotoxicity to Olaparib (%)

Ovarian

Penetrance

unknown

Moderate

unknown

Moderate

14.8%

Moderate

BRCA1 46%-87%

39%-63%

High

BRCA2 43%-84%

15%-27%

High

ATM 17%-52%
CHK2 23-48%
RAD51D unknown

Lifetime risks for breast and ovarian cancer determine penetrance
Stats provided by Myriad Genetics (https://myriad.com/)
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Figure 13. Plotting panel genes based on cell viability and pooled DNA damage sensitivity
after siRNA knock down correctly differentiates between moderate and high penetrance.
A. Plot with pooled DNA damage sensitivity data across all three reagents correctly indicates
ATM, RAD51D, CHK2 as moderately penetrance and BRCA1 and BRCA2 as high penetrant. B.
Etoposide incorrectly estimates CHK2 as highly penetrant and BRCA1 as moderately penetrant.
C. Cisplatin incorrectly estimates CHK2 as a highly penetrant gene D. Analysis of Olaparib
alone groups ATM with scramble control.
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5.4.2 CHK1 and RAD1 predicted as moderate to high and TP53I3 as moderate penetrant
genes
As previously discussed, plotting panel genes based on cell viability and pooled
cytotoxicity to DNA damage after siRNA knock down may differentiate between moderate and
high penetrance. In total, six control data points; scramble (SCR), ATM, CHK2, RAD51D,
BRCA1 and BRCA2 represent an accurate comparison for estimating the penetrance of candidate
genes. I therefore plotted these data points once more alongside non-panel candidate genes.
Again, with reduction in cell viability observed without drug exposure on the Y axis and
cytotoxicity observed after DNA damage (Cisplatin, Etoposide, Olaparib) on the X axis (Figure
14). Table 11 lists the statistical data from overall survival across all conditions by siRNA
knockdown.
In this analysis, MCM4, HMMR and REC8 were observed to cluster with the scramble
(SCR) control suggesting they are unlikely to be BRCA-like tumor suppressor genes. There is no
statistical difference between these candidate genes and the scramble control in overall mean
survival.

While REC8 deficient cells showed low but significant sensitivity to Etoposide

treatment, the difference between scramble control and pooled DNA treatment sensitivity plus
plating efficiency (cell viability after knock-down) was insignificant (p=0.06). In the plot for
estimating penetrance, candidate gene TP53I3 clustered with moderately penetrant genes and had
a survival of 36% (p=<0.001) across all conditions versus the survival of cells with siRNA
scramble control at 49.6%. CHK1 fell in a graphical position indicative of a gene with moderate
to high penetrance as the loss of cellular viability without DNA damage was observed as similar
to BRCA1 and BRCA2, however the sensitivity observed in response to DNA damaging reagents
was similar to moderately penetrant genes. The mean pooled survival for cells deficient in CHK1
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for all conditions was 32.7% (p=0.001). Of all candidate genes assayed, RAD1 was shown to be
the most impactful regarding cell survival and cytotoxicity to DNA damage. Cells deficient for
this gene had a survival rate of 26.8% (p=<0.001) across all conditions and this gene fell close to
BRCA1 and BRCA2 on the graphical representation of estimated penetrance, indicating that it
may be a highly penetrant gene (Table 11).
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HIGH

MODERATE

CONTROL

Cytotoxicity to DNA damage (%)

Figure 14. Penetrance estimates based on clustering with known risk genes
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Pooled survival rates (%)

Non-Panel

Panel

all conditions

Gene
Scramble
ATM
BRCA1
BRCA2
CHK2
RAD51D
FANCM
CHK1
HMMR
MCM4
RAD1
REC8
TP53I3

M
49.6
37.5
22.2
14.8
30.1
38.6
2.1
32.7
46.5
48.4
26.8
44.1
36.0

SD
8.3
19.89
15.54
10.27
12.95
12.92
1.83
19.70
13.79
12.17
13.12
11.51
11.61

MD
--12.0
27.4
34.7
19.5
11.0
47.5
16.8
3.0
1.2
22.8
5.5
13.6

t
---2.60
-7.71
-13.34
-6.30
-3.72
-26.9
-3.89
-0.96
-0.41
-7.31
-1.89
-4.90

p
--0.015
0.000
0.000
0.000
0.001
0.000
0.001
0.342
0.684
0.000
0.066
0.000

Table 11. Statistical data for pooled survival rates across all clonogenic survival conditions;
no drug, Cisplatin, Etoposide and Olaparib. M = Mean % survival, SD = Standard deviation,
MD = mean difference as compared to scramble control. t = statistical test for mean difference,
p-values in bold are significant.
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CHAPTER 6: DISCUSSION PART II
6.1 Functional analyses compliment bioinformatics and strengthen cases for various
novel risk genes
During WES analysis, various candidate genes were found with loss of function
mutations in women with OVCA and high risk of genetic inheritance.

While compelling

variants are often identified through WES/WGS, they remain putative risk loci until proven
otherwise. Because high risk variants are rare, and hereditary OVCA has a great deal of
heterogeneity, implicating a novel gene or variant based on enrichment in cases versus controls
is unlikely.

Additionally, implicating a variant based on segregation is not ideal due to

incomplete penetrance and lack of informative family members. Bioinformatic tools alone are
not sensitive enough to direct clinical decisions but are useful for variant filtering purposes.
This study is unique in its ability to identify novel risk loci for two main reasons; first,
WES was carried out on a very select group of patients with high risk of genetic inheritance, yet
with no known pathogenic variant.

Second, candidate loci identified by well-established

bioinformatics techniques were followed up by functional assessment using sensitive wet lab
techniques. This approach identified four novel genes; FANCM, CHK1, RAD1 and TP53I3 as
having the BRCA-like phenotype typically observed in tumor suppressor genes commonly
mutated the germline of women with inherited risk of breast and/or ovarian cancer.
In this study, siRNA knock-down of FANCM led to a reduction in homologous
recombination repair and large loss of clonogenic survival similar to that observed in BRCA1 or
BRCA2 deficient cells. Because of the large loss in cell survival after knock-down, it could not
be assayed for cytotoxicity to Cisplatin, Olaparib, or Etoposide after knock-down and therefore
an estimate of this gene’s penetrance could not be established. However, the functional data

96
from this study, along with the family pedigree of the FANCM carrier (Figure 7), and association
with familial breast cancer in recent literature (Peterlongo et al. 2015) is supportive of high risk.
Additionally, mouse model data describes FANCM homozygous knock outs as having decreased
life span and increased cancer incidence (Bakker et al., 2009).
Candidate gene CHK1, like panel gene CHK2, encodes for a serine/threonine protein
kinase required for checkpoint-mediated cell cycle arrest and activation of DNA repair by
homologous recombination repair. This gene is highly conserved, and the c.1564-1565insA
frameshift variant identified by WES in this study sample is novel. In this study, siRNA knock
down of CHK1 lead to a loss of HRR efficiency, reduction in cellular viability, and increased
sensitivity to Cisplatin and Etoposide similar to that of observed in BRCA1/BRCA2 deficient
cells. Loss of function of this gene is predicted to be moderate to highly penetrant in cancer risk
as it clusters with known high and moderate penetrant tumor suppressor genes on a 2dimensional model of cell viability and cytotoxicity to DNA damage.

These results are

consistent with mouse model phenotypes describing homozygote nulls are embryonic lethal, and
heterozygote knock-outs display enhanced tumorigenesis (Q. Liu et al., 2000). Recently, CHK1
has been identified as an important biomarker for chemotherapy response in breast cancer (AlKaabi et al. 2015) and the deletion of CHK1 is a common genetic event that occurs in the
beginning stages of breast cancer development (Mu et al., 2011). Loss of heterozygosity is likely
to have occurred in the carrier of the CHK1 frameshift. Unfortunately, the patient declined
tumor tissue usage, and this could not be confirmed. The fact that CHK1 has not already been
implicated in in hereditary risk of ovarian or breast cancer is likely because pathogenic variants
in this gene are extremely rare.
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Another novel loss of function variant was uncovered in RAD1. Knock out mouse
models of this gene describe embryonic lethality in homozygotes and larger, more numerous,
earlier onset skin tumors with DMBA-TPA treatment in heterozygotes (L. Han et al., 2010). In
this study, siRNA knock down of RAD1 led to decreased cellular viability and increased
sensitivity to Cisplatin, and Etoposide similar to that observed with knock down of BRCA1 and
BRCA2. However, RAD1 depletion did not lead to a reduction in HRR efficiency. This indicates
that RAD1 may be involved in DNA repair via a mechanism other than HRR. Most of what is
known regarding RAD1 functional activity is derived from yeast studies. RAD1 is a part of the
9-1-1 cell cycle checkpoint complex to arrest cellular proliferation in the presence of incomplete
DNA replication or damaged DNA. This complex has also been shown to participate in DNA
repair by forming a clamp to facilitate resection of DNA double strand breaks points (Ngo and
Lydall 2015). One study has shown RAD1 as indispensable to microhomology-mediated end
joining (MMEJ) for the repair of ionizing radiation and chemicals that induce DSBs (Ma et al.
2003). Another study in yeast identified RAD1 mutants as hyper sensitive to platinum (Perego et
al. 1998). While the human orthologue of yeast Rad1 is not well described in the literature, the
observation of a germline RAD1 LOF variant in an OVCA patient considered at high risk of
genetic inheritance, plus the results of this study’s functional analyses in a human cervical cell
line makes a compelling case for this gene as a risk factor. The scale of penetrance developed in
this study estimates the LOF of RAD1 to be high risk. The carrier of the RAD1 frameshift
variant developed OVCA at the age of 65, and had a family history of colon, breast (n=2),
prostate, lung, and leukemia all of which on one parental side of the family, which is indicative
of a highly penetrant germline risk variant. Unfortunately, segregation analysis was not possible
since DNA samples from her deceased family members are not available.
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TP53I3 is an oxidoreductase-like protein and an inducer of ROS, that is transcriptionally
activated by the tumor suppressor TP53 and likely to be involved in TP53-mediated apoptosis
(Zhang et al. 2015). A nonsense SNP in this gene was observed twice in this study sample
amongst unrelated individuals, despite its rarity (rs145078765, p.S252*, MAF= 0.0009). The
functional analysis of this gene during this study indicated that loss of TP53I3 leads to a
moderate reduction in HRR efficiency as well as increased cell sensitivity to Cisplatin. Loss of
function of this gene is predicted to be moderately penetrant in cancer risk as it clusters with
known moderately penetrant tumor suppressor genes on a 2-dimensional graphical representation
of cell viability and DNA sensitivity.
Another candidate gene assessed in this study was REC8, which encodes for a cohesin
complex protein required for the structural maintenance of chromosomes during meiosis.
Cohesions are necessary to join sister chromatids together until DNA replication is complete.
Rec8 functional studies in yeast described it as a meiosis-specific (Yoon et al. 2016). However,
in this study, siRNA reduction of REC8 led to a decrease in DNA repair by homologous
recombination and increased sensitivity to Etoposide. Because the pooled data across all
clonogenic survival conditions did not reach not significance (p=.06), this may indicate that
REC8 LOF would be of minimal risk, and possibly a modifier of penetrance. However, as
mentioned previously, the methods employed in this study are specific to capture a BRCA-like
tumor suppressor phenotype. It is possible that the tumor suppressor functions of REC8 are
mostly independent of DNA repair pathway. Recently, investigators identified REC8 as a tumor
suppressor gene epigenetically downregulated in gastric cancer (Yu et al. 2017). Another study
showed that epigenetic silencing of REC8 was robustly associated with PI3K pathway alterations
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in thyroid tumors, possibly encouraging the oncogenic properties of the PI3K/AKT/mTOR
pathway, which is important to cell cycle regulation (D. Liu et al., 2015).

6.2 A Novel scale for estimating penetrance through a 2-dimensional model of cell
viability and DNA sensitivity
Most cancer-associated risk loci have incomplete penetrance. The penetrance of a
pathogenic variant is determined by its associated lifetime risk with disease, and accurate
estimates of genetic penetrance are necessary to inform clinical decisions. Genes are often
described as having low, moderate, or high penetrance based on the lifetime risk associated with
a loss of function variant. Unfortunately, lifetime risk estimates are difficult to obtain with rare
variants and even well-established cancer risk loci can have unknown penetrance. Currently,
there exists no laboratory-based functional method for the specific purpose of estimating
penetrance of genetic loci in HBOC.
Candidate tumor suppressors are often assayed in conjunction with a BRCA1 or BRCA2
positive control since these genes are the two most highly penetrant in HBOC risk. The term
“BRCAness” or “BRCA-like” has come to describe other tumor suppressor genes that lead to
similar phenotypes with loss of function, such as sensitivity to DNA damage and loss of cell
viability. Various HBOC risk loci that possess BRCA-like tumor suppressor properties have been
implicated in the last decade. Many risk loci are described as moderately penetrant due to
lifetime risks estimated to be much higher than the general population, yet much lower than
BRCA1 or BRCA2. In this study, all lab experimental designs incorporated the use of five
positive controls for the comparison of novel candidate risk genes to two highly and three
moderately penetrant established risk genes in the context of BRCA-like tumor suppressor
properties.
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The assays employed in this study were sensitive enough to implicate all five established
HBOC cancer risk genes tested. Importantly, a pooled analysis of cell viability and cytotoxicity
to DNA damage was able to clearly distinguish between moderate and high-risk genes in a 2dimentional geographical representation. Notably, this technique estimated candidate genes
CHK1 and RAD1 as moderate to high and TP53I3 as moderately penetrant genes.
While preliminary, this scale has the potential to functionally validate additional
candidate genes identified by other WES studies and possibly estimate the penetrance of certain
established HBOC risk genes with unknown lifetime risk profiles (RAD50, BRIP1, BARD1, etc.)
This approach could eventually serve as a tool to better inform clinical management of certain
patients. Genetic testing clinics that engage in research may choose to employ this methodology
to help in closing the gap in missing heritability of this disease.

6.3 Limitations and Future Directions
It is important to note the various limitations of this study. Firstly, because WES targets
exonic DNA, it was only possible to analyze the protein coding and closely surrounding regions
on the genome in these high-risk women. While bioinformatic analysis was performed on the
1000 bps captured upstream of the exons of panel genes, no suspicious variants were uncovered
in either promoter or splice donor/acceptor loci. Additionally, large copy number variants
(CNVs) are not readily detectable through WES data and could be a source of missing
heritability. Using ExomeDepth, an R package which relies on read depth to indirectly infer
deletions or duplications, I was able to analyze all exomes for possible CNVs in panel genes, but
no true calls were detected (data not shown).
Additionally, the candidate gene analysis performed was primarily focused on DNA
repair and cell cycle control as these are the two most commonly mutated pathways in HBOC. It
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is likely that risk loci occur outside of these pathways and further analyses of these exomes
should be performed with this in mind. However, one important consideration in pathway
analysis of WES data is that it is far easier to determine that a variant leading to a loss of
function versus a gain of function by sequence change.
Furthermore, it must be emphasized that the penetrance estimates derived from functional
studies are specific to a loss of function risk loci in BRCA-like tumor suppressor genes involved
in cell viability and/or DNA repair. Accordingly, the functional analysis employed in this study
suggests that candidate genes REC8, HMMR, and MCM4 lack the “BRCA-ness” tumor
suppressor phenotype typically observed in breast and ovarian cancer risk genes. However, we
cannot say for certain that they are not risk factors by other means. Still, the overall approach
may be applicable to develop similar penetrance estimate scales specific to other cancer related
pathways. Additionally, the use of siRNA for gene depletion is not optimal since the various
siRNA have different knock down efficiencies. This makes it difficult to accurately compare
phenotypic outcomes by gene knockdown. Finally, because this methodology is new, it should
be further validated, refined, and replicated in additional cell lines, and preferably by employing
gene knock out techniques in place of mRNA depletion.
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APPENDIX
Gene

dbSNP ID

MAF

OBS

APEX1*

Amino
Acids
P248L

SIFT

Polyphen

1

HGMD (cancer phenotype
associated with gene)
Head and Neck

rs201100630

0.00005

DEL

Benign

AXIN1

V340M

rs143974067

0.00004

1

Colorectal adenoma

DEL

Probably Damaging

BUB1B

E409D

CASP10*

I406L

rs28989188

0.0004

1

Gastrointestinal

TOL

Probably Damaging

rs80358239

0.004

1

TOL

Possibly Damaging

E875G

rs1800124

0.019

1

DEL

Possibly Damaging

ERCC6

M713V

rs201486862

0.00006

1

DEL

Benign

EXO1*

D270V

rs201509012

0.0005

1

Autoimmune lymphoproliferative
syndrome II
Lung, Cockayne, Xeroderma
pigmentosa, Breast/Ovarian,
Fanconi anaemia,
Cockayne syndrome, basal cell
carcinoma,
Colorectal

ERCC4*

DEL

Possibly Damaging

EXO1*

G759E

rs4150001

0.009

1

Colorectal

TOL

Benign

FANCA*

T475M

N/A

N/A

1

Fanconi Anemia

DEL

Possibly Damaging

FANCA*

A602G

N/A

N/A

1

Fanconi Anemia

DEL

Possibly Damaging

FANCF*

P320L

rs45451294

0.017

2

Fanconi Anemia

TOL

Probably Damaging

MLH3*

V741F

rs28756990

0.006

1

Colorectal, Breast/Ovarian,

TOL

Possibly Damaging

PALLD*

R303S

rs138897963

0.001

1

Pancreatic

TOL

Probably Damaging

PMS1*

T75I

rs61756360

0.0008

1

Breast/ovarian

DEL

Probably Damaging

RAD50*

T191I

rs2230017

0.0007

1

Breast/Ovarian

DEL

Benign

RBL1*

R199H

N/A

N/A

1

Multiple adenoma

DEL

Probably Damaging

RBL1*

E624Q

N/A

N/A

1

Multiple adenoma

TOL

Possibly Damaging

RECQL

C321Y

rs150889040

0.00001

1

Breast

N/A

N/A

WRN*

T573A

rs150148567

0.001

1

Colorectal, Breast, Pancreatic,
Werner syndrome

DEL

Probably Damaging

Table 12. Rare missense variants in non-HBOC panel genes involved in DNA repair or cell
cycle control and are associated with cancer phenotypes in HGMD. MAF=Minor Allele
Frequency in (ExAC Non-Finnish Europeans.).

DEL= Deleterious TOL= Tolerated, N/A=

Information not available, *Variants in these genes were not confirmed by Sanger DNA
sequencing.
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+

- + - +

-

BRCA1
VINCULIN
ATM
VINCULIN
CHK1
ACTIN
RAD1
ACTIN
TP53I3
ACTIN
MCM4
ACTIN
HMMR
ACTIN
CHEK2

ACTIN

Figure 15. Western blots for siRNA knock down. Lysates from functional assays indicating
protein expression with scramble (+) and reduction of same protein with targeted siRNA knock
down (-) compared to Actin or Vinculin loading control.
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While 25% of ovarian cancer (OVCA) cases are due to inherited factors, most of the
genetic risk remains unexplained. This study addressed this gap by identifying previously
undescribed OVCA risk loci through the whole exome sequencing (WES) of 48 BRCA1/BRCA2
wild type women diagnosed with OVCA, selected for high risk of genetic inheritance. Five
clearly pathogenic variants were identified in this sample, four of which are in two genes
featured on current multi-gene panels; (RAD51D, ATM). In addition, a high impact variant in
FANCM (R1931*) was identified. FANCM has been recently implicated in familial breast
cancer risk but is not yet featured on testing panels.

Numerous rare and predicted to be

damaging variants of unknown significance were detected in genes on current commercial
testing panels. Also, the BRCA2 variant p.K3326*, considered benign but resulting in a 93
amino acid truncation, was overrepresented in our sample (OR= 4.95, p=0.01) and coexisted in
the germline of these women with other deleterious variants, suggesting a possible role as a
modifier of genetic penetrance.
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A candidate gene analysis detected loss of function (LOF) variants in genes involved in
OVCA relevant pathways; DNA repair and cell cycle control, including FANCM, CHK1,
TP53I3, REC8, HMMR, RAD1, and MCM4. Wet lab functional assessment implicated FANCM,
CHK1, RAD1 and TP53I3 as having the BRCA-like phenotype typically observed in tumor
suppressor genes commonly mutated the germline of women with inherited risk of breast and/or
ovarian cancer. Importantly, plotting various panel genes based on cell viability and sensitivity
to DNA damage after siRNA knock down correctly differentiated between moderate and high
penetrant genes. This technique identified candidate genes CHK1 and RAD1 as high and TP53I3
as moderate in penetrance.
The results of this project indicate that WES on study samples filtered for family history
and negative for known causal variants is the most appropriate study design for identifying rare
and novel high-risk variants. This study implicates novel risk loci as well as highlights the
necessity of wet lab functional assessment. Importantly, this study also suggests that wet lab
assays may be employed to differentiate moderate from high risk genetic loci.
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